country_code,country_name,year,income_class,gavi_spec,gavi_supported,vax_target,vax_doses,vax_fd_cov,who_reg,HPV_INT_DOSES,has_vax_nat_schedule,first_year_vax_intro,type_prim_deliv_vax,age_adm_vax,sex_adm_vax,cerv_can_cr_rate_2022
ABW,Aruba,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ABW,Aruba,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
AFG,Afghanistan,2008,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2009,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2010,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2011,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2012,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2013,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2014,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2015,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2016,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2017,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2018,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2019,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2020,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2021,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2022,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2023,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2024,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AFG,Afghanistan,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,6.1
AGO,Angola,2008,LM,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2009,LM,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2010,LM,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2011,UM,Graduating,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2012,UM,Graduating,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2013,UM,Graduating,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2014,UM,Graduating,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2015,UM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2016,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2017,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2018,LM,Fully self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2019,LM,Fully self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2020,LM,Fully self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2021,LM,Fully self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2022,LM,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2023,LM,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2024,LM,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
AGO,Angola,2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,9-12,Female,16.0
ALB,Albania,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2011,LM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2019,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2020,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2021,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2022,UM,N/A,not supported by gavi,15648.0,2761.0,18.0,EUR,1 dose,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2023,UM,N/A,not supported by gavi,15605.0,6402.0,41.0,EUR,1 dose,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2024,UM,N/A,not supported by gavi,15681.0,6771.0,43.0,EUR,1 dose,Yes,2022.0,Facility-based,13,Female,12.2
ALB,Albania,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,Facility-based,13,Female,12.2
AND,Andorra,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2018,H,N/A,not supported by gavi,N/A,N/A,49.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2019,H,N/A,not supported by gavi,N/A,N/A,64.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2020,H,N/A,not supported by gavi,N/A,N/A,77.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2021,H,N/A,not supported by gavi,N/A,N/A,83.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2022,H,N/A,not supported by gavi,N/A,N/A,83.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2023,H,N/A,not supported by gavi,N/A,N/A,85.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2024,H,N/A,not supported by gavi,N/A,N/A,92.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,N/A
AND,Andorra,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,12,Both sexes,N/A
ARE,United Arab Emirates,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2014,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2015,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2016,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2017,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2018,H,N/A,not supported by gavi,39096.0,9837.0,25.0,EMR,2 doses (6 months),Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2019,H,N/A,not supported by gavi,39174.0,10353.0,26.0,EMR,2 doses (6 months),Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2020,H,N/A,not supported by gavi,43368.0,18729.0,43.0,EMR,2 doses (6 months),Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2021,H,N/A,not supported by gavi,45048.0,16968.0,38.0,EMR,2 doses (6 months),Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2022,H,N/A,not supported by gavi,47436.0,17390.0,37.0,EMR,2 doses (6 months),Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2023,H,N/A,not supported by gavi,50586.0,18910.0,37.0,EMR,2 doses (6 months),Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2024,H,N/A,not supported by gavi,54140.0,27720.0,51.0,EMR,2 doses (6 months),Yes,2018.0,School-based,13,Both sexes,4.4
ARE,United Arab Emirates,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,School-based,13,Both sexes,4.4
ARG,Argentina,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2011,UM,N/A,not supported by gavi,342901.0,216553.0,63.0,AMR,1 dose,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2012,UM,N/A,not supported by gavi,340851.0,240112.0,70.0,AMR,1 dose,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2013,UM,N/A,not supported by gavi,339142.0,289736.0,85.0,AMR,1 dose,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2014,H,N/A,not supported by gavi,338016.0,286800.0,85.0,AMR,1 dose,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2015,UM,N/A,not supported by gavi,337947.0,287342.0,85.0,AMR,1 dose,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2016,UM,N/A,not supported by gavi,346509.0,297507.0,86.0,AMR,1 dose,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2017,H,N/A,not supported by gavi,347500.0,296906.0,85.0,AMR,1 dose,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2018,UM,N/A,not supported by gavi,352411.0,316470.0,90.0,AMR,1 dose,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2019,UM,N/A,not supported by gavi,355138.0,309712.0,87.0,AMR,1 dose,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2020,UM,N/A,not supported by gavi,358281.0,255300.0,71.0,AMR,1 dose,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2021,UM,N/A,not supported by gavi,368495.0,279790.0,76.0,AMR,1 dose,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2022,UM,N/A,not supported by gavi,374369.0,309140.0,83.0,AMR,1 dose,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2023,UM,N/A,not supported by gavi,356756.0,223675.0,63.0,AMR,1 dose,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2024,UM,N/A,not supported by gavi,361147.0,199364.0,55.0,AMR,1 dose,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARG,Argentina,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2011.0,Varies by region/province,11,Both sexes,19.9
ARM,Armenia,2008,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2009,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2010,LM,Least Poor,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2011,LM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2012,LM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2013,LM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2014,LM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2015,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2016,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2017,UM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,EUR,1 dose,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2018,UM,Fully self-financing,supported by gavi,17148.0,1070.0,6.0,EUR,1 dose,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2019,UM,Fully self-financing,supported by gavi,17464.0,3006.0,17.0,EUR,1 dose,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2020,UM,Fully self-financing,supported by gavi,17803.0,1783.0,10.0,EUR,1 dose,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2021,UM,Fully self-financing,supported by gavi,18178.0,1750.0,10.0,EUR,1 dose,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2022,UM,mic_former_gavi,supported by gavi,18660.0,7577.0,41.0,EUR,1 dose,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2023,UM,mic_former_gavi,supported by gavi,18916.0,8165.0,43.0,EUR,1 dose,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2024,UM,mic_former_gavi,supported by gavi,19330.0,7341.0,38.0,EUR,1 dose,Yes,2017.0,Facility-based,14,Female,9.9
ARM,Armenia,2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,Facility-based,14,Female,9.9
ASM,American Samoa,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2010,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2011,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2012,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2013,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2014,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2015,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2016,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2017,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2018,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2019,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2020,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2021,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ASM,American Samoa,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
ATG,Antigua and Barbuda,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2014,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2015,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2016,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2017,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2018,H,N/A,not supported by gavi,3216.0,345.0,11.0,AMR,2 doses (6 months),Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2019,H,N/A,not supported by gavi,N/A,N/A,11.0,AMR,2 doses (6 months),Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,AMR,2 doses (6 months),Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2021,H,N/A,not supported by gavi,N/A,N/A,2.0,AMR,2 doses (6 months),Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2022,H,N/A,not supported by gavi,N/A,N/A,2.0,AMR,2 doses (6 months),Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2023,H,N/A,not supported by gavi,2938.0,45.0,2.0,AMR,2 doses (6 months),Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2024,H,N/A,not supported by gavi,N/A,N/A,2.0,AMR,2 doses (6 months),Yes,2018.0,Facility-based,9-13,Both sexes,N/A
ATG,Antigua and Barbuda,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,Facility-based,9-13,Both sexes,N/A
AUS,Australia,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2010,H,N/A,not supported by gavi,135413.0,105657.0,78.0,WPR,1 dose,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2011,H,N/A,not supported by gavi,136106.0,103235.0,76.0,WPR,1 dose,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2012,H,N/A,not supported by gavi,136829.0,104102.0,76.0,WPR,1 dose,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2013,H,N/A,not supported by gavi,136751.0,96873.0,71.0,WPR,1 dose,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2014,H,N/A,not supported by gavi,N/A,N/A,74.0,WPR,1 dose,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2015,H,N/A,not supported by gavi,137036.0,104082.0,76.0,WPR,1 dose,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2016,H,N/A,not supported by gavi,N/A,N/A,79.0,WPR,1 dose,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2017,H,N/A,not supported by gavi,142468.0,119154.0,84.0,WPR,1 dose,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2018,H,N/A,not supported by gavi,N/A,N/A,85.0,WPR,1 dose,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2019,H,N/A,not supported by gavi,154214.0,136636.0,89.0,WPR,1 dose,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2020,H,N/A,not supported by gavi,157594.0,116791.0,74.0,WPR,1 dose,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2021,H,N/A,not supported by gavi,N/A,N/A,74.0,WPR,1 dose,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2022,H,N/A,not supported by gavi,159857.0,120605.0,75.0,WPR,1 dose,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2023,H,N/A,not supported by gavi,160040.0,112884.0,71.0,WPR,1 dose,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2024,H,N/A,not supported by gavi,160411.0,117843.0,73.0,WPR,1 dose,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUS,Australia,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,School-based,12-13,Both sexes,6.9
AUT,Austria,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2014,H,N/A,not supported by gavi,N/A,N/A,23.0,EUR,2 doses (6 months),Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2015,H,N/A,not supported by gavi,N/A,N/A,24.0,EUR,2 doses (6 months),Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2016,H,N/A,not supported by gavi,N/A,N/A,20.0,EUR,2 doses (6 months),Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2017,H,N/A,not supported by gavi,N/A,N/A,19.0,EUR,2 doses (6 months),Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2018,H,N/A,not supported by gavi,N/A,N/A,56.0,EUR,2 doses (6 months),Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2019,H,N/A,not supported by gavi,N/A,N/A,59.0,EUR,2 doses (6 months),Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2020,H,N/A,not supported by gavi,N/A,N/A,58.0,EUR,2 doses (6 months),Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2021,H,N/A,not supported by gavi,N/A,N/A,57.0,EUR,2 doses (6 months),Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2022,H,N/A,not supported by gavi,N/A,N/A,50.0,EUR,2 doses (6 months),Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2023,H,N/A,not supported by gavi,N/A,N/A,56.0,EUR,2 doses (6 months),Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2024,H,N/A,not supported by gavi,41959.0,22394.0,53.0,EUR,2 doses (6 months),Yes,2014.0,School-based,9,Both sexes,8.9
AUT,Austria,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,9,Both sexes,8.9
AZE,Azerbaijan,2008,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2009,UM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2010,UM,Least Poor,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2011,UM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2012,UM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2013,UM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2014,UM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2015,UM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2016,UM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2017,UM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2018,UM,Fully self-financing,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2019,UM,Fully self-financing,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2020,UM,Fully self-financing,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2021,UM,Fully self-financing,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2022,UM,mic_former_gavi,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2023,UM,mic_former_gavi,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2024,UM,mic_former_gavi,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,10.6
AZE,Azerbaijan,2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,10.6
BDI,Burundi,2008,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2009,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2010,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2011,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2012,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2013,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2014,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2015,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2016,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2017,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2018,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2019,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2020,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2021,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2022,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2023,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2024,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BDI,Burundi,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.9
BEL,Belgium,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2012,H,N/A,not supported by gavi,N/A,N/A,1.0,EUR,2 doses (6 months),Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2013,H,N/A,not supported by gavi,N/A,N/A,66.0,EUR,2 doses (6 months),Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2014,H,N/A,not supported by gavi,N/A,N/A,67.0,EUR,2 doses (6 months),Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2015,H,N/A,not supported by gavi,N/A,N/A,69.0,EUR,2 doses (6 months),Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2016,H,N/A,not supported by gavi,N/A,N/A,70.0,EUR,2 doses (6 months),Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2017,H,N/A,not supported by gavi,N/A,N/A,72.0,EUR,2 doses (6 months),Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2018,H,N/A,not supported by gavi,N/A,N/A,74.0,EUR,2 doses (6 months),Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2019,H,N/A,not supported by gavi,N/A,N/A,75.0,EUR,2 doses (6 months),Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2020,H,N/A,not supported by gavi,N/A,N/A,77.0,EUR,2 doses (6 months),Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2021,H,N/A,not supported by gavi,N/A,N/A,77.0,EUR,2 doses (6 months),Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2022,H,N/A,not supported by gavi,N/A,N/A,77.0,EUR,2 doses (6 months),Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2023,H,N/A,not supported by gavi,N/A,N/A,80.0,EUR,2 doses (6 months),Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2024,H,N/A,not supported by gavi,N/A,N/A,80.0,EUR,2 doses (6 months),Yes,2007.0,School-based,12-14,Both sexes,9.0
BEL,Belgium,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,School-based,12-14,Both sexes,9.0
BEN,Benin,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2010,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2011,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2012,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2013,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2014,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2015,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2016,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2017,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2018,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2019,LM,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2020,LM,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2021,LM,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2022,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2023,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2024,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BEN,Benin,2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School.based,9-14,Female,11.0
BFA,Burkina Faso,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2010,L,Poorest,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2011,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2012,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2013,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2014,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2015,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2016,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2017,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2018,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2019,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2020,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2021,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2022,L,Initial self-financing,supported by gavi,317729.0,221752.0,70.0,AFR,1 dose,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2023,L,Initial self-financing,supported by gavi,323281.0,311894.0,96.0,AFR,1 dose,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2024,L,Initial self-financing,supported by gavi,335340.0,345592.0,99.0,AFR,1 dose,Yes,2022.0,School-based,9,Female,8.9
BFA,Burkina Faso,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,School-based,9,Female,8.9
BGD,Bangladesh,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2010,L,Poorest,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2011,L,Low income,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2012,L,Low income,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2013,L,Low income,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2014,LM,Low income,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2015,LM,Initial self-financing,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2017,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2018,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2019,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2020,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2021,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2022,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2023,LM,Accelerated transition phase,supported by gavi,7854289.0,1494423.0,19.0,SEAR,1 dose,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2024,LM,Accelerated transition phase,supported by gavi,6483338.0,5857586.0,90.0,SEAR,1 dose,Yes,2023.0,N/A,10-14,Female,11.6
BGD,Bangladesh,2025,N/A,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,N/A,10-14,Female,11.6
BGR,Bulgaria,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2013,UM,N/A,not supported by gavi,31085.0,7470.0,0.0,EUR,2 doses (6 months),Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2014,UM,N/A,not supported by gavi,29931.0,4633.0,0.0,EUR,2 doses (6 months),Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2015,UM,N/A,not supported by gavi,60028.0,3759.0,0.0,EUR,2 doses (6 months),Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2016,UM,N/A,not supported by gavi,61051.0,2651.0,0.0,EUR,2 doses (6 months),Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2017,UM,N/A,not supported by gavi,62563.0,3115.0,5.0,EUR,2 doses (6 months),Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2018,UM,N/A,not supported by gavi,63648.0,4610.0,7.0,EUR,2 doses (6 months),Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2019,UM,N/A,not supported by gavi,64538.0,4272.0,7.0,EUR,2 doses (6 months),Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2020,UM,N/A,not supported by gavi,65949.0,2431.0,4.0,EUR,2 doses (6 months),Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2021,UM,N/A,not supported by gavi,136849.0,3003.0,2.0,EUR,2 doses (6 months),Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2022,UM,N/A,not supported by gavi,34978.0,1488.0,4.0,EUR,2 doses (6 months),Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2023,H,N/A,not supported by gavi,34896.0,2017.0,6.0,EUR,2 doses (6 months),Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2024,H,N/A,not supported by gavi,33704.0,3745.0,11.0,EUR,2 doses (6 months),Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BGR,Bulgaria,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,Facility-based,12-13,Both sexes,24.9
BHR,Bahrain,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2014,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2015,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2016,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2017,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2018,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2019,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2020,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2021,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2022,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,EMR,2 doses (6 months),Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2024,H,N/A,not supported by gavi,9573.0,7046.0,74.0,EMR,2 doses (6 months),Yes,2023.0,N/A,12-13,Both sexes,2.9
BHR,Bahrain,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,N/A,12-13,Both sexes,2.9
BHS,"Bahamas, The",2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2010,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2011,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2012,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2013,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2014,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2015,H,N/A,not supported by gavi,5453.0,193.0,4.0,AMR,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2016,H,N/A,not supported by gavi,5535.0,1347.0,24.0,AMR,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2017,H,N/A,not supported by gavi,5618.0,944.0,17.0,AMR,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2018,H,N/A,not supported by gavi,5676.0,676.0,12.0,AMR,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2019,H,N/A,not supported by gavi,5708.0,889.0,16.0,AMR,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2020,H,N/A,not supported by gavi,5637.0,367.0,7.0,AMR,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2021,H,N/A,not supported by gavi,N/A,N/A,7.0,AMR,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2022,H,N/A,not supported by gavi,2779.0,256.0,9.0,AMR,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2023,H,N/A,not supported by gavi,2656.0,431.0,16.0,AMR,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2024,H,N/A,not supported by gavi,2634.0,652.0,25.0,AMR,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BHS,"Bahamas, The",2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2015.0,School-based,9-10,Both sexes,20.4
BIH,Bosnia and Herzegovina,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2019,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2020,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2021,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2022,UM,N/A,not supported by gavi,15563.0,319.0,2.0,EUR,2 doses (6 months),Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2023,UM,N/A,not supported by gavi,15428.0,875.0,6.0,EUR,2 doses (6 months),Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2024,UM,N/A,not supported by gavi,14550.0,492.0,3.0,EUR,2 doses (6 months),Yes,2022.0,mixed,11-14,Both sexes,15.9
BIH,Bosnia and Herzegovina,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,mixed,11-14,Both sexes,15.9
BLR,Belarus,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2019,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2020,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2021,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2022,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2023,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2024,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2025.0,School-based,11-14,Female,13.3
BLR,Belarus,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,11-14,Female,13.3
BLZ,Belize,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2010,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2011,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2016,UM,N/A,not supported by gavi,3809.0,2092.0,55.0,AMR,1 dose,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2017,UM,N/A,not supported by gavi,3772.0,2103.0,56.0,AMR,1 dose,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2018,UM,N/A,not supported by gavi,3725.0,2201.0,59.0,AMR,1 dose,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2019,UM,N/A,not supported by gavi,3692.0,2848.0,77.0,AMR,1 dose,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2020,LM,N/A,not supported by gavi,3546.0,1903.0,54.0,AMR,1 dose,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2021,UM,N/A,not supported by gavi,3453.0,290.0,8.0,AMR,1 dose,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2022,UM,mic_never_gavi,supported by gavi,3508.0,2928.0,83.0,AMR,1 dose,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2023,UM,mic_never_gavi,supported by gavi,3615.0,1817.0,50.0,AMR,1 dose,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2024,UM,mic_never_gavi,supported by gavi,3691.0,2276.0,62.0,AMR,1 dose,Yes,2016.0,School-based,9-14,Both sexes,16.4
BLZ,Belize,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,School-based,9-14,Both sexes,16.4
BMU,Bermuda,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BMU,Bermuda,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
BOL,Bolivia,2008,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,Bolivia,2009,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,Bolivia,2010,LM,Least Poor,supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,Bolivia,2011,LM,Graduating,supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,Bolivia,2012,LM,Graduating,supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,Bolivia,2013,LM,Graduating,supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,Bolivia,2014,LM,Graduating,supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,Bolivia,2015,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,Bolivia,2016,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,Bolivia,2017,LM,Accelerated transition phase,supported by gavi,347868.0,257105.0,74.0,AMR,1 dose,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,Bolivia,2018,LM,Fully self-financing,supported by gavi,117959.0,81726.0,69.0,AMR,1 dose,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,Bolivia,2019,LM,Fully self-financing,supported by gavi,118397.0,91511.0,77.0,AMR,1 dose,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,Bolivia,2020,LM,Fully self-financing,supported by gavi,118852.0,68422.0,58.0,AMR,1 dose,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,Bolivia,2021,LM,Fully self-financing,supported by gavi,119288.0,69339.0,58.0,AMR,1 dose,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,Bolivia,2022,LM,mic_former_gavi,supported by gavi,119672.0,88156.0,74.0,AMR,1 dose,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,Bolivia,2023,LM,mic_former_gavi,supported by gavi,119984.0,82002.0,68.0,AMR,1 dose,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,Bolivia,2024,LM,mic_former_gavi,supported by gavi,120177.0,94292.0,78.0,AMR,1 dose,Yes,2017.0,School-based,10,Both sexes,37.0
BOL,"Bolivia, Plurinational State of",2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,School-based,10,Both sexes,37.0
BRA,Brazil,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2013,UM,N/A,not supported by gavi,N/A,N/A,N/A,AMR,1 dose,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2014,UM,N/A,not supported by gavi,4743847.0,4958969.0,99.0,AMR,1 dose,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2015,UM,N/A,not supported by gavi,4534884.0,3476086.0,77.0,AMR,1 dose,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2016,UM,N/A,not supported by gavi,1471979.0,1239305.0,84.0,AMR,1 dose,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2017,UM,N/A,not supported by gavi,1447211.0,1714478.0,99.0,AMR,1 dose,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2018,UM,N/A,not supported by gavi,1590611.0,1221986.0,77.0,AMR,1 dose,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2019,UM,N/A,not supported by gavi,1590611.0,1217112.0,77.0,AMR,1 dose,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2020,UM,N/A,not supported by gavi,1590611.0,1400598.0,88.0,AMR,1 dose,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2021,UM,N/A,not supported by gavi,1440539.0,1167045.0,81.0,AMR,1 dose,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2022,UM,N/A,not supported by gavi,1455779.0,1221594.0,84.0,AMR,1 dose,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2023,UM,N/A,not supported by gavi,1426299.0,1122935.0,79.0,AMR,1 dose,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2024,UM,N/A,not supported by gavi,1407147.0,1112787.0,79.0,AMR,1 dose,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRA,Brazil,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,Facility-based,9-14,Both sexes,17.1
BRB,Barbados,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2014,H,N/A,not supported by gavi,1825.0,394.0,22.0,AMR,1 dose,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2015,H,N/A,not supported by gavi,1804.0,1364.0,76.0,AMR,1 dose,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2016,H,N/A,not supported by gavi,1786.0,1531.0,86.0,AMR,1 dose,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2017,H,N/A,not supported by gavi,1754.0,655.0,37.0,AMR,1 dose,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2018,H,N/A,not supported by gavi,1765.0,1138.0,64.0,AMR,1 dose,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2019,H,N/A,not supported by gavi,1843.0,1137.0,62.0,AMR,1 dose,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2020,H,N/A,not supported by gavi,1838.0,1080.0,59.0,AMR,1 dose,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2021,H,N/A,not supported by gavi,1741.0,640.0,37.0,AMR,1 dose,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2022,H,N/A,not supported by gavi,1682.0,718.0,43.0,AMR,1 dose,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2023,H,N/A,not supported by gavi,1646.0,782.0,48.0,AMR,1 dose,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2024,H,N/A,not supported by gavi,1622.0,704.0,43.0,AMR,1 dose,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRB,Barbados,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,10-11,Both sexes,24.3
BRN,Brunei Darussalam,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2012,H,N/A,not supported by gavi,7522.0,6859.0,91.0,WPR,2 doses (6 months),Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2013,H,N/A,not supported by gavi,6755.0,6017.0,89.0,WPR,2 doses (6 months),Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2014,H,N/A,not supported by gavi,6785.0,5666.0,84.0,WPR,2 doses (6 months),Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2015,H,N/A,not supported by gavi,6809.0,5402.0,79.0,WPR,2 doses (6 months),Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2016,H,N/A,not supported by gavi,3362.0,2934.0,87.0,WPR,2 doses (6 months),Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2017,H,N/A,not supported by gavi,3313.0,2901.0,88.0,WPR,2 doses (6 months),Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2018,H,N/A,not supported by gavi,3215.0,2898.0,90.0,WPR,2 doses (6 months),Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2019,H,N/A,not supported by gavi,3095.0,2823.0,91.0,WPR,2 doses (6 months),Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2020,H,N/A,not supported by gavi,2978.0,2622.0,88.0,WPR,2 doses (6 months),Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2021,H,N/A,not supported by gavi,2947.0,2745.0,93.0,WPR,2 doses (6 months),Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2022,H,N/A,not supported by gavi,2987.0,2644.0,89.0,WPR,2 doses (6 months),Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2023,H,N/A,not supported by gavi,2994.0,2747.0,92.0,WPR,2 doses (6 months),Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2024,H,N/A,not supported by gavi,3056.0,2823.0,92.0,WPR,2 doses (6 months),Yes,2012.0,mixed,13,Female,24.7
BRN,Brunei Darussalam,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2012.0,mixed,13,Female,24.7
BTN,Bhutan,2008,LM,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2009,LM,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2010,LM,Poorest,supported by gavi,6840.0,6301.0,92.0,SEAR,1 dose,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2011,LM,Graduating,supported by gavi,6756.0,5590.0,83.0,SEAR,1 dose,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2012,LM,Graduating,supported by gavi,6795.0,5708.0,84.0,SEAR,1 dose,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2013,LM,Graduating,supported by gavi,6851.0,5755.0,84.0,SEAR,1 dose,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2014,LM,Graduating,supported by gavi,6901.0,6763.0,98.0,SEAR,1 dose,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2015,LM,Accelerated transition phase,supported by gavi,6968.0,6759.0,97.0,SEAR,1 dose,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2016,LM,Fully self-financing,supported by gavi,7004.0,6800.0,97.0,SEAR,1 dose,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2017,LM,Fully self-financing,supported by gavi,6915.0,6642.0,96.0,SEAR,1 dose,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2018,LM,Fully self-financing,supported by gavi,6701.0,6432.0,96.0,SEAR,1 dose,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2019,LM,Fully self-financing,supported by gavi,6450.0,5873.0,91.0,SEAR,1 dose,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2020,LM,Fully self-financing,supported by gavi,6253.0,5490.0,88.0,SEAR,1 dose,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2021,LM,Fully self-financing,supported by gavi,6159.0,5733.0,93.0,SEAR,1 dose,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2022,LM,mic_former_gavi,supported by gavi,6145.0,5430.0,88.0,SEAR,1 dose,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2023,LM,mic_former_gavi,supported by gavi,6160.0,5601.0,91.0,SEAR,1 dose,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2024,LM,mic_former_gavi,supported by gavi,6168.0,5772.0,94.0,SEAR,1 dose,Yes,2009.0,School-based,12,Both sexes,13.3
BTN,Bhutan,2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,School-based,12,Both sexes,13.3
BWA,Botswana,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2015,UM,N/A,not supported by gavi,93285.0,71054.0,76.0,AFR,2 doses (6 months),Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2016,UM,N/A,not supported by gavi,24331.0,22809.0,94.0,AFR,2 doses (6 months),Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2017,UM,N/A,not supported by gavi,24587.0,22002.0,89.0,AFR,2 doses (6 months),Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2019,UM,N/A,not supported by gavi,24605.0,21592.0,88.0,AFR,2 doses (6 months),Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2020,UM,N/A,not supported by gavi,49061.0,26727.0,54.0,AFR,2 doses (6 months),Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2021,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2022,UM,N/A,not supported by gavi,24564.0,3747.0,15.0,AFR,2 doses (6 months),Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2023,UM,N/A,not supported by gavi,49160.0,37208.0,76.0,AFR,2 doses (6 months),Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2024,UM,N/A,not supported by gavi,N/A,N/A,93.0,AFR,2 doses (6 months),Yes,2015.0,School-based,9-13,Female,36.1
BWA,Botswana,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2015.0,School-based,9-13,Female,36.1
CAF,Central African Republic,2008,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2009,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2010,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2011,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2012,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2013,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2014,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2015,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2016,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2017,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2018,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2019,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2020,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2021,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2022,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2023,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2024,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAF,Central African Republic,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,11.7
CAN,Canada,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,AMR,1 dose,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,AMR,1 dose,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,AMR,1 dose,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2013,H,N/A,not supported by gavi,N/A,N/A,73.0,AMR,1 dose,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2014,H,N/A,not supported by gavi,N/A,N/A,74.0,AMR,1 dose,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2015,H,N/A,not supported by gavi,N/A,N/A,75.0,AMR,1 dose,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2016,H,N/A,not supported by gavi,N/A,N/A,79.0,AMR,1 dose,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2017,H,N/A,not supported by gavi,N/A,N/A,83.0,AMR,1 dose,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2018,H,N/A,not supported by gavi,N/A,N/A,83.0,AMR,1 dose,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2019,H,N/A,not supported by gavi,N/A,N/A,83.0,AMR,1 dose,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2020,H,N/A,not supported by gavi,N/A,N/A,87.0,AMR,1 dose,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2021,H,N/A,not supported by gavi,N/A,N/A,87.0,AMR,1 dose,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2022,H,N/A,not supported by gavi,N/A,N/A,86.0,AMR,1 dose,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2023,H,N/A,not supported by gavi,N/A,N/A,86.0,AMR,1 dose,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2024,H,N/A,not supported by gavi,N/A,N/A,86.0,AMR,1 dose,Yes,2009.0,School-based,12,Both sexes,9.0
CAN,Canada,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,School-based,12,Both sexes,9.0
CHE,Switzerland,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2010,H,N/A,not supported by gavi,N/A,N/A,26.0,EUR,2 doses (6 months),Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2011,H,N/A,not supported by gavi,N/A,N/A,56.0,EUR,2 doses (6 months),Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2012,H,N/A,not supported by gavi,N/A,N/A,56.0,EUR,2 doses (6 months),Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2013,H,N/A,not supported by gavi,N/A,N/A,56.0,EUR,2 doses (6 months),Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2014,H,N/A,not supported by gavi,N/A,N/A,59.0,EUR,2 doses (6 months),Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2015,H,N/A,not supported by gavi,N/A,N/A,59.0,EUR,2 doses (6 months),Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2016,H,N/A,not supported by gavi,N/A,N/A,59.0,EUR,2 doses (6 months),Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2017,H,N/A,not supported by gavi,N/A,N/A,64.0,EUR,2 doses (6 months),Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2018,H,N/A,not supported by gavi,N/A,N/A,64.0,EUR,2 doses (6 months),Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2019,H,N/A,not supported by gavi,N/A,N/A,64.0,EUR,2 doses (6 months),Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2020,H,N/A,not supported by gavi,N/A,N/A,67.0,EUR,2 doses (6 months),Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2021,H,N/A,not supported by gavi,N/A,N/A,74.0,EUR,2 doses (6 months),Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2022,H,N/A,not supported by gavi,N/A,N/A,74.0,EUR,2 doses (6 months),Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2023,H,N/A,not supported by gavi,N/A,N/A,77.0,EUR,2 doses (6 months),Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2024,H,N/A,not supported by gavi,N/A,N/A,78.0,EUR,2 doses (6 months),Yes,2006.0,mixed,11-14,Both sexes,6.1
CHE,Switzerland,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2006.0,mixed,11-14,Both sexes,6.1
CHI,Channel Islands,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHI,Channel Islands,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CHL,Chile,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2014,H,N/A,not supported by gavi,113585.0,96868.0,85.0,AMR,1 dose,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2015,H,N/A,not supported by gavi,113210.0,94867.0,84.0,AMR,1 dose,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2016,H,N/A,not supported by gavi,114549.0,90056.0,79.0,AMR,1 dose,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2017,H,N/A,not supported by gavi,117617.0,97498.0,83.0,AMR,1 dose,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2018,H,N/A,not supported by gavi,120097.0,107866.0,90.0,AMR,1 dose,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2019,H,N/A,not supported by gavi,121404.0,114286.0,94.0,AMR,1 dose,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2020,H,N/A,not supported by gavi,121549.0,96836.0,80.0,AMR,1 dose,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2021,H,N/A,not supported by gavi,121206.0,94955.0,78.0,AMR,1 dose,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2022,H,N/A,not supported by gavi,121210.0,113345.0,94.0,AMR,1 dose,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2023,H,N/A,not supported by gavi,121550.0,106546.0,88.0,AMR,1 dose,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2024,H,N/A,not supported by gavi,121322.0,113705.0,94.0,AMR,1 dose,Yes,2014.0,School-based,9,Both sexes,16.0
CHL,Chile,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,9,Both sexes,16.0
CHN,China,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2010,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2011,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2012,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2013,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2014,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2015,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2016,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2017,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2018,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2019,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2020,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2021,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2022,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2023,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2024,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CHN,China,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,mixed,13,Female,21.8
CIV,Cte d'Ivoire,2008,LM,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2009,LM,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2010,LM,Fragile,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2011,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2012,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2013,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2014,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2017,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2018,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2019,LM,Preparatory transition phase,supported by gavi,371097.0,21515.0,6.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2020,LM,Preparatory transition phase,supported by gavi,376875.0,229706.0,61.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2021,LM,Preparatory transition phase,supported by gavi,2170371.0,601359.0,28.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2022,LM,Accelerated transition phase,supported by gavi,766680.0,339952.0,44.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2023,LM,Accelerated transition phase,supported by gavi,585642.0,429638.0,73.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2024,LM,Accelerated transition phase,supported by gavi,616683.0,374731.0,61.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,17.1
CIV,Cte d'Ivoire,2025,N/A,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9,Female,17.1
CMR,Cameroon,2008,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2009,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2010,LM,Least Poor,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2011,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2012,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2013,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2014,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2017,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2018,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2019,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2020,LM,Preparatory transition phase,supported by gavi,349524.0,16440.0,5.0,AFR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2021,LM,Preparatory transition phase,supported by gavi,355717.0,73956.0,21.0,AFR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2022,LM,Preparatory transition phase,supported by gavi,362022.0,84299.0,23.0,AFR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2023,LM,Preparatory transition phase,supported by gavi,368931.0,249498.0,68.0,AFR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2024,LM,Preparatory transition phase,supported by gavi,379781.0,138515.0,36.0,AFR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.1
CMR,Cameroon,2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2020.0,School-based,9,Both sexes,18.1
COD,"Congo, Dem. Rep.",2008,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Dem. Rep.",2009,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Dem. Rep.",2010,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Dem. Rep.",2011,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Dem. Rep.",2012,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Dem. Rep.",2013,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Dem. Rep.",2014,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Dem. Rep.",2015,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Dem. Rep.",2016,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Dem. Rep.",2017,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Dem. Rep.",2018,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Dem. Rep.",2019,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Dem. Rep.",2020,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Dem. Rep.",2021,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Dem. Rep.",2022,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Dem. Rep.",2023,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Dem. Rep.",2024,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COD,"Congo, Democratic Republic of",2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.3
COG,"Congo, Rep.",2008,LM,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,"Congo, Rep.",2009,LM,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,"Congo, Rep.",2010,LM,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,"Congo, Rep.",2011,LM,Graduating,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,"Congo, Rep.",2012,LM,Graduating,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,"Congo, Rep.",2013,LM,Graduating,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,"Congo, Rep.",2014,LM,Graduating,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,"Congo, Rep.",2015,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,"Congo, Rep.",2016,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,"Congo, Rep.",2017,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,"Congo, Rep.",2018,LM,Fully self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,"Congo, Rep.",2019,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,"Congo, Rep.",2020,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,"Congo, Rep.",2021,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,"Congo, Rep.",2022,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,"Congo, Rep.",2023,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,"Congo, Rep.",2024,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COG,Congo,2025,N/A,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.7
COK,Cook Island,2010,N/A,N/A,N/A,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2011.0,School-based,9,Female,N/A
COK,Cook Island,2011,N/A,N/A,N/A,481.0,362.0,75.0,WPR,2 doses (6 months),Yes,2011.0,School-based,9,Female,N/A
COK,Cook Island,2012,N/A,N/A,N/A,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2011.0,School-based,9,Female,N/A
COK,Cook Island,2013,N/A,N/A,N/A,242.0,269.0,99.0,WPR,2 doses (6 months),Yes,2011.0,School-based,9,Female,N/A
COK,Cook Island,2014,N/A,N/A,N/A,98.0,118.0,99.0,WPR,2 doses (6 months),Yes,2011.0,School-based,9,Female,N/A
COK,Cook Island,2015,N/A,N/A,N/A,132.0,126.0,95.0,WPR,2 doses (6 months),Yes,2011.0,School-based,9,Female,N/A
COK,Cook Island,2016,N/A,N/A,N/A,108.0,86.0,80.0,WPR,2 doses (6 months),Yes,2011.0,School-based,9,Female,N/A
COK,Cook Island,2017,N/A,N/A,N/A,108.0,41.0,38.0,WPR,2 doses (6 months),Yes,2011.0,School-based,9,Female,N/A
COK,Cook Island,2018,N/A,N/A,N/A,144.0,139.0,97.0,WPR,2 doses (6 months),Yes,2011.0,School-based,9,Female,N/A
COK,Cook Island,2019,N/A,N/A,N/A,N/A,N/A,97.0,WPR,2 doses (6 months),Yes,2011.0,School-based,9,Female,N/A
COK,Cook Island,2020,N/A,N/A,N/A,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2011.0,School-based,9,Female,N/A
COK,Cook Island,2021,N/A,N/A,N/A,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2011.0,School-based,9,Female,N/A
COK,Cook Island,2022,N/A,N/A,N/A,387.0,53.0,14.0,WPR,2 doses (6 months),Yes,2011.0,School-based,9,Female,N/A
COK,Cook Island,2023,N/A,N/A,N/A,133.0,122.0,92.0,WPR,2 doses (6 months),Yes,2011.0,School-based,9,Female,N/A
COK,Cook Island,2024,N/A,N/A,N/A,113.0,87.0,77.0,WPR,2 doses (6 months),Yes,2011.0,School-based,9,Female,N/A
COL,Colombia,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2012,UM,N/A,not supported by gavi,405573.0,362076.0,89.0,AMR,1 dose,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2013,UM,N/A,not supported by gavi,2447302.0,1572662.0,64.0,AMR,1 dose,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2014,UM,N/A,not supported by gavi,392563.0,143541.0,37.0,AMR,1 dose,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2015,UM,N/A,not supported by gavi,384607.0,101182.0,26.0,AMR,1 dose,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2016,UM,N/A,not supported by gavi,379983.0,22689.0,6.0,AMR,1 dose,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2017,UM,N/A,not supported by gavi,378299.0,58479.0,15.0,AMR,1 dose,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2018,UM,N/A,not supported by gavi,375452.0,105353.0,28.0,AMR,1 dose,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2019,UM,N/A,not supported by gavi,368190.0,114025.0,31.0,AMR,1 dose,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2020,UM,N/A,not supported by gavi,359591.0,106285.0,30.0,AMR,1 dose,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2021,UM,N/A,not supported by gavi,354985.0,139767.0,39.0,AMR,1 dose,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2022,UM,N/A,not supported by gavi,352996.0,134111.0,38.0,AMR,1 dose,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2023,UM,N/A,not supported by gavi,350634.0,187370.0,53.0,AMR,1 dose,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2024,UM,N/A,not supported by gavi,346938.0,208686.0,60.0,AMR,1 dose,Yes,2012.0,School-based,9-17,Both sexes,17.4
COL,Colombia,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2012.0,School-based,9-17,Both sexes,17.4
COM,Comoros,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2010,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2011,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2012,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2013,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2014,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2015,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2016,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2017,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2018,LM,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2019,LM,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2020,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2021,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2022,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2023,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2024,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
COM,Comoros,2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,N/A,36.3
CPV,Cabo Verde,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2010,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2011,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2012,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2013,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2014,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2015,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2016,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2017,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2018,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2019,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2020,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2021,LM,N/A,not supported by gavi,4819.0,4635.0,96.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2022,LM,mic_never_gavi,supported by gavi,4819.0,4917.0,99.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2023,LM,mic_never_gavi,supported by gavi,4790.0,4896.0,99.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2024,UM,mic_never_gavi,supported by gavi,4765.0,4979.0,99.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Both sexes,16.3
CPV,Cabo Verde,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,N/A,N/A,Both sexes,16.3
CRI,Costa Rica,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2019,UM,N/A,not supported by gavi,36339.0,35722.0,98.0,AMR,2 doses (6 months),Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2020,UM,N/A,not supported by gavi,35041.0,29359.0,84.0,AMR,2 doses (6 months),Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2021,UM,N/A,not supported by gavi,34621.0,19686.0,57.0,AMR,2 doses (6 months),Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2022,UM,N/A,not supported by gavi,35105.0,30011.0,85.0,AMR,2 doses (6 months),Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2023,UM,N/A,not supported by gavi,34390.0,27041.0,79.0,AMR,2 doses (6 months),Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2024,H,N/A,not supported by gavi,35074.0,32423.0,92.0,AMR,2 doses (6 months),Yes,2019.0,School-based,10,Both sexes,13.1
CRI,Costa Rica,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,10,Both sexes,13.1
CUB,Cuba,2008,UM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2009,UM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2010,UM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2011,UM,Graduating,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2012,UM,Graduating,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2013,UM,Graduating,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2014,UM,Graduating,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2015,UM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2016,UM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2017,UM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2018,UM,Fully self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2019,UM,Fully self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2020,UM,Fully self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2021,UM,Fully self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2022,UM,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2023,UM,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2024,UM,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUB,Cuba,2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,4th Grade (9-11),Female,19.7
CUW,Curaao,2008,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2009,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CUW,Curaao,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYM,Cayman Islands,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
CYP,Cyprus,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2014,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2015,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2016,H,N/A,not supported by gavi,8640.0,4932.0,57.0,EUR,2 doses (6 months),Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2017,H,N/A,not supported by gavi,4380.0,2552.0,58.0,EUR,2 doses (6 months),Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2018,H,N/A,not supported by gavi,4380.0,2575.0,59.0,EUR,2 doses (6 months),Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2019,H,N/A,not supported by gavi,4506.0,3270.0,73.0,EUR,2 doses (6 months),Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2021,H,N/A,not supported by gavi,N/A,N/A,84.0,EUR,2 doses (6 months),Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2022,H,N/A,not supported by gavi,4668.0,3256.0,70.0,EUR,2 doses (6 months),Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2023,H,N/A,not supported by gavi,4761.0,3636.0,76.0,EUR,2 doses (6 months),Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2024,H,N/A,not supported by gavi,4887.0,4063.0,83.0,EUR,2 doses (6 months),Yes,2016.0,School-based,11-14,Both sexes,10.1
CYP,Cyprus,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,School-based,11-14,Both sexes,10.1
CZE,Czechia,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2012,H,N/A,not supported by gavi,43849.0,32394.0,74.0,EUR,2 doses (6 months),Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2013,H,N/A,not supported by gavi,44041.0,32297.0,73.0,EUR,2 doses (6 months),Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2014,H,N/A,not supported by gavi,44688.0,31213.0,70.0,EUR,2 doses (6 months),Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2015,H,N/A,not supported by gavi,45607.0,30140.0,66.0,EUR,2 doses (6 months),Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2016,H,N/A,not supported by gavi,46322.0,28763.0,62.0,EUR,2 doses (6 months),Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2017,H,N/A,not supported by gavi,47221.0,30270.0,64.0,EUR,2 doses (6 months),Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2018,H,N/A,not supported by gavi,49088.0,31462.0,64.0,EUR,2 doses (6 months),Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2019,H,N/A,not supported by gavi,51165.0,33793.0,66.0,EUR,2 doses (6 months),Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2020,H,N/A,not supported by gavi,54421.0,38216.0,70.0,EUR,2 doses (6 months),Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2021,H,N/A,not supported by gavi,57753.0,40880.0,71.0,EUR,2 doses (6 months),Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2022,H,N/A,not supported by gavi,N/A,N/A,71.0,EUR,2 doses (6 months),Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2023,H,N/A,not supported by gavi,58528.0,40880.0,70.0,EUR,2 doses (6 months),Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2024,H,N/A,not supported by gavi,55791.0,41970.0,75.0,EUR,2 doses (6 months),Yes,2012.0,Facility-based,13,Both sexes,12.1
CZE,Czechia,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2012.0,Facility-based,13,Both sexes,12.1
DEU,Germany,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2010,H,N/A,not supported by gavi,N/A,N/A,40.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2011,H,N/A,not supported by gavi,N/A,N/A,40.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2012,H,N/A,not supported by gavi,N/A,N/A,40.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2013,H,N/A,not supported by gavi,N/A,N/A,43.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2014,H,N/A,not supported by gavi,N/A,N/A,45.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2015,H,N/A,not supported by gavi,N/A,N/A,48.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2016,H,N/A,not supported by gavi,N/A,N/A,51.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2017,H,N/A,not supported by gavi,N/A,N/A,54.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2018,H,N/A,not supported by gavi,N/A,N/A,58.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2019,H,N/A,not supported by gavi,N/A,N/A,63.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2020,H,N/A,not supported by gavi,N/A,N/A,66.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2021,H,N/A,not supported by gavi,N/A,N/A,67.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2022,H,N/A,not supported by gavi,N/A,N/A,68.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2023,H,N/A,not supported by gavi,N/A,N/A,68.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2024,H,N/A,not supported by gavi,N/A,N/A,68.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DEU,Germany,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,9-14,Both sexes,10.7
DJI,Djibouti,2008,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2009,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2010,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2011,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2012,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2013,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2014,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2017,LM,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2018,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2019,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2020,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2021,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2022,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2023,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2024,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DJI,Djibouti,2025,N/A,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,14.7
DMA,Dominica,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2019,UM,N/A,not supported by gavi,474.0,405.0,85.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2020,UM,N/A,not supported by gavi,473.0,413.0,87.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2021,UM,N/A,not supported by gavi,454.0,344.0,76.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2022,UM,mic_never_gavi,supported by gavi,550.0,456.0,83.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2023,UM,mic_never_gavi,supported by gavi,428.0,298.0,70.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2024,UM,mic_never_gavi,supported by gavi,431.0,331.0,77.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,N/A
DMA,Dominica,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,11-12,Both sexes,N/A
DNK,Denmark,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2011,H,N/A,not supported by gavi,33884.0,22000.0,65.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2012,H,N/A,not supported by gavi,34127.0,22654.0,66.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2013,H,N/A,not supported by gavi,34507.0,29771.0,86.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2014,H,N/A,not supported by gavi,33665.0,26298.0,78.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2015,H,N/A,not supported by gavi,32887.0,23347.0,71.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2016,H,N/A,not supported by gavi,33242.0,15768.0,47.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2017,H,N/A,not supported by gavi,33360.0,19352.0,58.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2018,H,N/A,not supported by gavi,33293.0,24491.0,74.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2019,H,N/A,not supported by gavi,33409.0,26234.0,79.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2020,H,N/A,not supported by gavi,33681.0,30037.0,89.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2021,H,N/A,not supported by gavi,33824.0,31085.0,92.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2022,H,N/A,not supported by gavi,32726.0,29093.0,89.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2023,H,N/A,not supported by gavi,33032.0,29641.0,90.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2024,H,N/A,not supported by gavi,31221.0,27937.0,89.0,EUR,2 doses (6 months),Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DNK,Denmark,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,12.7
DOM,Dominican Republic,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2017,UM,N/A,not supported by gavi,192220.0,113417.0,59.0,AMR,1 dose,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2018,UM,N/A,not supported by gavi,99463.0,55805.0,56.0,AMR,1 dose,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2019,UM,N/A,not supported by gavi,100884.0,9645.0,10.0,AMR,1 dose,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2020,UM,N/A,not supported by gavi,101162.0,8044.0,8.0,AMR,1 dose,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2021,UM,N/A,not supported by gavi,101042.0,19403.0,19.0,AMR,1 dose,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2022,UM,N/A,not supported by gavi,100758.0,21228.0,21.0,AMR,1 dose,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2023,UM,N/A,not supported by gavi,100429.0,41873.0,42.0,AMR,1 dose,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2024,UM,N/A,not supported by gavi,100037.0,45004.0,45.0,AMR,1 dose,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DOM,Dominican Republic,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,Facility-based,9-14,Both sexes,17.5
DZA,Algeria,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2010,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2011,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2012,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2013,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2014,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2015,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2016,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2017,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2018,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2019,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2020,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2021,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2022,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2023,UM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2024,UM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
DZA,Algeria,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,8.0
ECU,Ecuador,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2014,UM,N/A,not supported by gavi,491567.0,455363.0,93.0,AMR,1 dose,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2015,UM,N/A,not supported by gavi,167334.0,184795.0,99.0,AMR,1 dose,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2016,UM,N/A,not supported by gavi,164225.0,166038.0,99.0,AMR,1 dose,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2017,UM,N/A,not supported by gavi,165006.0,147874.0,90.0,AMR,1 dose,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2018,UM,N/A,not supported by gavi,165315.0,161359.0,98.0,AMR,1 dose,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2019,UM,N/A,not supported by gavi,165234.0,136033.0,82.0,AMR,1 dose,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2020,UM,N/A,not supported by gavi,159812.0,116038.0,73.0,AMR,1 dose,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2021,UM,N/A,not supported by gavi,159127.0,45532.0,29.0,AMR,1 dose,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2022,UM,N/A,not supported by gavi,163962.0,161471.0,98.0,AMR,1 dose,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2023,UM,N/A,not supported by gavi,148522.0,119166.0,80.0,AMR,1 dose,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2024,UM,N/A,not supported by gavi,156237.0,139611.0,89.0,AMR,1 dose,Yes,2014.0,School-based,9-14,Both sexes,19.8
ECU,Ecuador,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,9-14,Both sexes,19.8
EGY,"Egypt, Arab Rep.",2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,"Egypt, Arab Rep.",2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,"Egypt, Arab Rep.",2010,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,"Egypt, Arab Rep.",2011,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,"Egypt, Arab Rep.",2012,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,"Egypt, Arab Rep.",2013,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,"Egypt, Arab Rep.",2014,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,"Egypt, Arab Rep.",2015,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,"Egypt, Arab Rep.",2016,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,"Egypt, Arab Rep.",2017,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,"Egypt, Arab Rep.",2018,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,"Egypt, Arab Rep.",2019,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,"Egypt, Arab Rep.",2020,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,"Egypt, Arab Rep.",2021,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,"Egypt, Arab Rep.",2022,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,"Egypt, Arab Rep.",2023,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,"Egypt, Arab Rep.",2024,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
EGY,Egypt,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.5
ERI,Eritrea,2008,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2009,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2010,L,Fragile,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2011,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2012,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2013,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2014,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2015,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2016,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2017,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2018,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2019,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2020,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2021,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2022,L,Initial self-financing,supported by gavi,262596.0,224764.0,86.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2023,L,Initial self-financing,supported by gavi,84012.0,28248.0,34.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2024,L,Initial self-financing,supported by gavi,49348.0,33387.0,68.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,10.7
ERI,Eritrea,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,N/A,Female,10.7
ESP,Spain,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2010,H,N/A,not supported by gavi,N/A,N/A,61.0,EUR,1 dose,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2011,H,N/A,not supported by gavi,N/A,N/A,66.0,EUR,1 dose,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2012,H,N/A,not supported by gavi,N/A,N/A,71.0,EUR,1 dose,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2013,H,N/A,not supported by gavi,N/A,N/A,73.0,EUR,1 dose,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2014,H,N/A,not supported by gavi,N/A,N/A,71.0,EUR,1 dose,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2015,H,N/A,not supported by gavi,N/A,N/A,79.0,EUR,1 dose,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2016,H,N/A,not supported by gavi,N/A,N/A,82.0,EUR,1 dose,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2017,H,N/A,not supported by gavi,231820.0,193478.0,83.0,EUR,1 dose,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2018,H,N/A,not supported by gavi,223015.0,189417.0,85.0,EUR,1 dose,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2019,H,N/A,not supported by gavi,229109.0,204776.0,89.0,EUR,1 dose,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2020,H,N/A,not supported by gavi,N/A,N/A,89.0,EUR,1 dose,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2021,H,N/A,not supported by gavi,228771.0,206375.0,90.0,EUR,1 dose,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2022,H,N/A,not supported by gavi,227721.0,205005.0,90.0,EUR,1 dose,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2023,H,N/A,not supported by gavi,237741.0,211521.0,89.0,EUR,1 dose,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2024,H,N/A,not supported by gavi,N/A,N/A,90.0,EUR,1 dose,Yes,2007.0,mixed,12,Both sexes,8.5
ESP,Spain,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,mixed,12,Both sexes,8.5
EST,Estonia,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2014,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2015,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2016,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2017,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2018,H,N/A,not supported by gavi,19713.0,10226.0,52.0,EUR,1 dose,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2019,H,N/A,not supported by gavi,7184.0,3991.0,56.0,EUR,1 dose,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2020,H,N/A,not supported by gavi,7543.0,4531.0,60.0,EUR,1 dose,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2021,H,N/A,not supported by gavi,7652.0,4830.0,63.0,EUR,1 dose,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2022,H,N/A,not supported by gavi,7776.0,3944.0,51.0,EUR,1 dose,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2023,H,N/A,not supported by gavi,7662.0,4456.0,58.0,EUR,1 dose,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2024,H,N/A,not supported by gavi,N/A,N/A,63.0,EUR,1 dose,Yes,2018.0,School-based,12-18,Both sexes,17.4
EST,Estonia,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,School-based,12-18,Both sexes,17.4
ETH,Ethiopia,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2010,L,Poorest,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2011,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2012,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2013,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2014,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2015,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2016,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2017,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2018,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,AFR,1 dose,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2019,L,Initial self-financing,supported by gavi,1410443.0,691117.0,49.0,AFR,1 dose,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2020,L,Initial self-financing,supported by gavi,1435445.0,703368.0,49.0,AFR,1 dose,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2021,L,Initial self-financing,supported by gavi,1452699.0,769930.0,53.0,AFR,1 dose,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2022,L,Initial self-financing,supported by gavi,1465329.0,879197.0,60.0,AFR,1 dose,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2023,L,Initial self-financing,supported by gavi,1469398.0,881639.0,60.0,AFR,1 dose,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2024,L,Initial self-financing,supported by gavi,9051552.0,5249900.0,58.0,AFR,1 dose,Yes,2018.0,School-based,9,Female,13.5
ETH,Ethiopia,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,School-based,9,Female,13.5
FIN,Finland,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2015,H,N/A,not supported by gavi,N/A,N/A,69.0,EUR,2 doses (6 months),Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2016,H,N/A,not supported by gavi,N/A,N/A,66.0,EUR,2 doses (6 months),Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2017,H,N/A,not supported by gavi,N/A,N/A,70.0,EUR,2 doses (6 months),Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2018,H,N/A,not supported by gavi,N/A,N/A,69.0,EUR,2 doses (6 months),Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2019,H,N/A,not supported by gavi,N/A,N/A,70.0,EUR,2 doses (6 months),Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2020,H,N/A,not supported by gavi,N/A,N/A,79.0,EUR,2 doses (6 months),Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2021,H,N/A,not supported by gavi,N/A,N/A,71.0,EUR,2 doses (6 months),Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2022,H,N/A,not supported by gavi,N/A,N/A,73.0,EUR,2 doses (6 months),Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2023,H,N/A,not supported by gavi,N/A,N/A,77.0,EUR,2 doses (6 months),Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2024,H,N/A,not supported by gavi,N/A,N/A,71.0,EUR,2 doses (6 months),Yes,2013.0,School-based,10-12,Both sexes,6.4
FIN,Finland,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,School-based,10-12,Both sexes,6.4
FJI,Fiji,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2010,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2011,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2013,UM,N/A,not supported by gavi,8063.0,7168.0,89.0,WPR,2 doses (6 months),Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2014,UM,N/A,not supported by gavi,8040.0,6691.0,83.0,WPR,2 doses (6 months),Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2015,UM,N/A,not supported by gavi,8123.0,6528.0,80.0,WPR,2 doses (6 months),Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2016,UM,N/A,not supported by gavi,8209.0,6791.0,83.0,WPR,2 doses (6 months),Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2017,UM,N/A,not supported by gavi,8262.0,6738.0,82.0,WPR,2 doses (6 months),Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2018,UM,N/A,not supported by gavi,8316.0,6619.0,80.0,WPR,2 doses (6 months),Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2019,UM,N/A,not supported by gavi,8399.0,7333.0,87.0,WPR,2 doses (6 months),Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2020,UM,N/A,not supported by gavi,8509.0,7148.0,84.0,WPR,2 doses (6 months),Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2021,UM,N/A,not supported by gavi,8528.0,6908.0,81.0,WPR,2 doses (6 months),Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2022,UM,mic_never_gavi,supported by gavi,8462.0,6521.0,77.0,WPR,2 doses (6 months),Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2023,UM,mic_never_gavi,supported by gavi,8396.0,7432.0,89.0,WPR,2 doses (6 months),Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2024,UM,mic_never_gavi,supported by gavi,8319.0,7432.0,89.0,WPR,2 doses (6 months),Yes,2013.0,School-based,13,Female,36.7
FJI,Fiji,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,School-based,13,Female,36.7
FRA,France,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2010,H,N/A,not supported by gavi,N/A,N/A,29.0,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2011,H,N/A,not supported by gavi,N/A,N/A,29.0,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2012,H,N/A,not supported by gavi,N/A,N/A,21.0,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2013,H,N/A,not supported by gavi,N/A,N/A,20.0,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2014,H,N/A,not supported by gavi,N/A,N/A,19.0,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2015,H,N/A,not supported by gavi,N/A,N/A,21.0,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2016,H,N/A,not supported by gavi,N/A,N/A,24.0,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2017,H,N/A,not supported by gavi,N/A,N/A,26.0,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2018,H,N/A,not supported by gavi,N/A,N/A,29.0,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2019,H,N/A,not supported by gavi,N/A,N/A,35.0,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2020,H,N/A,not supported by gavi,N/A,N/A,41.0,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2021,H,N/A,not supported by gavi,N/A,N/A,46.0,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2022,H,N/A,not supported by gavi,N/A,N/A,48.0,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2023,H,N/A,not supported by gavi,N/A,N/A,55.0,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2024,H,N/A,not supported by gavi,N/A,N/A,48.0,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRA,France,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2006.0,Facility-based,11-14,Both sexes,9.4
FRO,Faeroe Islands,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FRO,Faeroe Islands,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
FSM,"Micronesia, Fed. Sts.",2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,10,Female,N/A
FSM,"Micronesia, Fed. Sts.",2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,10,Female,N/A
FSM,"Micronesia, Fed. Sts.",2010,LM,N/A,not supported by gavi,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2010.0,School-based,10,Female,N/A
FSM,"Micronesia, Fed. Sts.",2011,LM,N/A,not supported by gavi,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2010.0,School-based,10,Female,N/A
FSM,"Micronesia, Fed. Sts.",2012,LM,N/A,not supported by gavi,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2010.0,School-based,10,Female,N/A
FSM,"Micronesia, Fed. Sts.",2013,LM,N/A,not supported by gavi,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2010.0,School-based,10,Female,N/A
FSM,"Micronesia, Fed. Sts.",2014,LM,N/A,not supported by gavi,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2010.0,School-based,10,Female,N/A
FSM,"Micronesia, Fed. Sts.",2015,LM,N/A,not supported by gavi,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2010.0,School-based,10,Female,N/A
FSM,"Micronesia, Fed. Sts.",2016,LM,N/A,not supported by gavi,1248.0,830.0,67.0,WPR,2 doses (6 months),Yes,2010.0,School-based,10,Female,N/A
FSM,"Micronesia, Fed. Sts.",2017,LM,N/A,not supported by gavi,1202.0,895.0,74.0,WPR,2 doses (6 months),Yes,2010.0,School-based,10,Female,N/A
FSM,"Micronesia, Fed. Sts.",2018,LM,N/A,not supported by gavi,1186.0,820.0,69.0,WPR,2 doses (6 months),Yes,2010.0,School-based,10,Female,N/A
FSM,"Micronesia, Fed. Sts.",2019,LM,N/A,not supported by gavi,1206.0,834.0,69.0,WPR,2 doses (6 months),Yes,2010.0,School-based,10,Female,N/A
FSM,"Micronesia, Fed. Sts.",2020,LM,N/A,not supported by gavi,3029.0,2378.0,79.0,WPR,2 doses (6 months),Yes,2010.0,School-based,10,Female,N/A
FSM,"Micronesia, Fed. Sts.",2021,LM,N/A,not supported by gavi,1190.0,934.0,79.0,WPR,2 doses (6 months),Yes,2010.0,School-based,10,Female,N/A
FSM,"Micronesia, Fed. Sts.",2022,LM,mic_never_gavi,supported by gavi,10889.0,7622.0,70.0,WPR,2 doses (6 months),Yes,2010.0,School-based,10,Female,N/A
FSM,"Micronesia, Fed. Sts.",2023,LM,mic_never_gavi,supported by gavi,5912.0,4138.0,70.0,WPR,2 doses (6 months),Yes,2010.0,School-based,10,Female,N/A
FSM,"Micronesia, Fed. Sts.",2024,LM,mic_never_gavi,supported by gavi,3393.0,2375.0,70.0,WPR,2 doses (6 months),Yes,2010.0,School-based,10,Female,N/A
FSM,Micronesia,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,10,Female,N/A
GAB,Gabon,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2010,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2011,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2012,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2013,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2014,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2015,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2016,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2017,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2018,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2019,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2020,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2021,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2022,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2023,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2024,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GAB,Gabon,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.7
GBR,United Kingdom,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2010,H,N/A,not supported by gavi,365592.0,308123.0,84.0,EUR,1 dose,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2011,H,N/A,not supported by gavi,359863.0,316043.0,88.0,EUR,1 dose,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2012,H,N/A,not supported by gavi,353303.0,319277.0,90.0,EUR,1 dose,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2013,H,N/A,not supported by gavi,346276.0,311470.0,90.0,EUR,1 dose,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2014,H,N/A,not supported by gavi,342910.0,308131.0,90.0,EUR,1 dose,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2015,H,N/A,not supported by gavi,N/A,N/A,88.0,EUR,1 dose,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2016,H,N/A,not supported by gavi,334490.0,302905.0,91.0,EUR,1 dose,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2017,H,N/A,not supported by gavi,342409.0,305676.0,89.0,EUR,1 dose,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2018,H,N/A,not supported by gavi,354658.0,316486.0,89.0,EUR,1 dose,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2019,H,N/A,not supported by gavi,363870.0,323910.0,89.0,EUR,1 dose,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2020,H,N/A,not supported by gavi,371587.0,330528.0,89.0,EUR,1 dose,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2021,H,N/A,not supported by gavi,374265.0,313012.0,84.0,EUR,1 dose,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2022,H,N/A,not supported by gavi,400216.0,331666.0,83.0,EUR,1 dose,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2023,H,N/A,not supported by gavi,399743.0,306458.0,77.0,EUR,1 dose,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2024,H,N/A,not supported by gavi,406809.0,305492.0,75.0,EUR,1 dose,Yes,2008.0,School-based,12-13,Both sexes,9.3
GBR,United Kingdom,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,School-based,12-13,Both sexes,9.3
GEO,Georgia,2008,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2009,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2010,LM,Least Poor,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2011,LM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2012,LM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2013,LM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2014,LM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2015,UM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2016,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2017,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2018,UM,Fully self-financing,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2019,UM,Fully self-financing,supported by gavi,70962.0,27210.0,38.0,EUR,2 doses (6 months),Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2020,UM,Fully self-financing,supported by gavi,75624.0,8955.0,12.0,EUR,2 doses (6 months),Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2021,UM,Fully self-financing,supported by gavi,26355.0,8893.0,34.0,EUR,2 doses (6 months),Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2022,UM,mic_former_gavi,supported by gavi,26004.0,12379.0,48.0,EUR,2 doses (6 months),Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2023,UM,mic_former_gavi,supported by gavi,26546.0,15432.0,58.0,EUR,2 doses (6 months),Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2024,UM,mic_former_gavi,supported by gavi,27939.0,9053.0,32.0,EUR,2 doses (6 months),Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GEO,Georgia,2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,Facility-based,10-12,Both sexes,15.9
GHA,Ghana,2008,L,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2009,L,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2010,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2011,LM,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2012,LM,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2013,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2014,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2017,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2018,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2019,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2020,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2021,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2022,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2023,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2024,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GHA,Ghana,2025,N/A,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,9-14,Female,19.2
GIB,Gibraltar,2008,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2011,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2012,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2013,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2014,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIB,Gibraltar,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
GIN,Guinea,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2010,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2011,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2012,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2013,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2014,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2015,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2016,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2017,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2018,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2019,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2020,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2021,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2022,LM,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2023,LM,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2024,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GIN,Guinea,2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,35.8
GMB,"Gambia, The",2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9-14,Female,25.2
GMB,"Gambia, The",2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9-14,Female,25.2
GMB,"Gambia, The",2010,L,Poorest,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9-14,Female,25.2
GMB,"Gambia, The",2011,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9-14,Female,25.2
GMB,"Gambia, The",2012,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9-14,Female,25.2
GMB,"Gambia, The",2013,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9-14,Female,25.2
GMB,"Gambia, The",2014,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9-14,Female,25.2
GMB,"Gambia, The",2015,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9-14,Female,25.2
GMB,"Gambia, The",2016,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9-14,Female,25.2
GMB,"Gambia, The",2017,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9-14,Female,25.2
GMB,"Gambia, The",2018,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9-14,Female,25.2
GMB,"Gambia, The",2019,L,Initial self-financing,supported by gavi,186123.0,119406.0,64.0,AFR,1 dose,Yes,2019.0,School-based,9-14,Female,25.2
GMB,"Gambia, The",2020,L,Initial self-financing,supported by gavi,191686.0,0.0,0.0,AFR,1 dose,Yes,2019.0,School-based,9-14,Female,25.2
GMB,"Gambia, The",2021,L,Initial self-financing,supported by gavi,35553.0,11340.0,32.0,AFR,1 dose,Yes,2019.0,School-based,9-14,Female,25.2
GMB,"Gambia, The",2022,L,Initial self-financing,supported by gavi,202879.0,0.0,0.0,AFR,1 dose,Yes,2019.0,School-based,9-14,Female,25.2
GMB,"Gambia, The",2023,L,Initial self-financing,supported by gavi,167146.0,40123.0,24.0,AFR,1 dose,Yes,2019.0,School-based,9-14,Female,25.2
GMB,"Gambia, The",2024,L,Initial self-financing,supported by gavi,160814.0,23527.0,15.0,AFR,1 dose,Yes,2019.0,School-based,9-14,Female,25.2
GMB,Gambia,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9-14,Female,25.2
GNB,Guinea-Bissau,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2010,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2011,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2012,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2013,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2014,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2015,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2016,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2017,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2018,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2019,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2020,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2021,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2022,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2023,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2024,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNB,Guinea-Bissau,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,21.3
GNQ,Equatorial Guinea,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2015,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2016,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2017,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2018,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2019,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2020,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2021,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2022,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2023,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2024,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GNQ,Equatorial Guinea,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,19.1
GRC,Greece,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRC,Greece,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,Facility-based,11-12,Both sexes,9.0
GRD,Grenada,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2019,UM,N/A,not supported by gavi,862.0,642.0,74.0,AMR,1 dose,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2020,UM,N/A,not supported by gavi,861.0,502.0,58.0,AMR,1 dose,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2021,UM,N/A,not supported by gavi,856.0,13.0,2.0,AMR,1 dose,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2022,UM,mic_never_gavi,supported by gavi,846.0,130.0,15.0,AMR,1 dose,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2023,UM,mic_never_gavi,supported by gavi,817.0,11.0,1.0,AMR,1 dose,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2024,UM,mic_never_gavi,supported by gavi,778.0,38.0,5.0,AMR,1 dose,Yes,2019.0,School-based,9,Female,N/A
GRD,Grenada,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9,Female,N/A
GRL,Greenland,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GRL,Greenland,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2007.0,Facility-based,12-14,Both sexes,N/A
GTM,Guatemala,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2010,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2011,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2012,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2013,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2014,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2015,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2016,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2018,UM,N/A,not supported by gavi,376604.0,210530.0,56.0,AMR,1 dose,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2019,UM,N/A,not supported by gavi,564562.0,173930.0,31.0,AMR,1 dose,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2020,UM,N/A,not supported by gavi,753553.0,175764.0,23.0,AMR,1 dose,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2021,UM,N/A,not supported by gavi,191179.0,67624.0,35.0,AMR,1 dose,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2022,UM,N/A,not supported by gavi,193215.0,49357.0,26.0,AMR,1 dose,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2023,UM,N/A,not supported by gavi,194440.0,92885.0,48.0,AMR,1 dose,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2024,UM,N/A,not supported by gavi,195590.0,110707.0,57.0,AMR,1 dose,Yes,2018.0,School-based,9-17,Both sexes,18.7
GTM,Guatemala,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,School-based,9-17,Both sexes,18.7
GUM,Guam,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUM,Guam,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,22.3
GUY,Guyana,2008,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2009,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2010,LM,Least Poor,supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2011,LM,Intermediate,supported by gavi,N/A,N/A,N/A,AMR,1 dose,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2012,LM,Intermediate,supported by gavi,31337.0,4327.0,14.0,AMR,1 dose,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2013,LM,Graduating,supported by gavi,30335.0,4774.0,16.0,AMR,1 dose,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2014,LM,Graduating,supported by gavi,29408.0,1323.0,4.0,AMR,1 dose,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2015,UM,Accelerated transition phase,supported by gavi,28680.0,572.0,2.0,AMR,1 dose,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2016,UM,Accelerated transition phase,supported by gavi,21114.0,3216.0,15.0,AMR,1 dose,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2017,UM,Fully self-financing,supported by gavi,21287.0,6539.0,31.0,AMR,1 dose,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2018,UM,Fully self-financing,supported by gavi,14976.0,4815.0,32.0,AMR,1 dose,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2019,UM,Fully self-financing,supported by gavi,12680.0,4692.0,37.0,AMR,1 dose,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2020,UM,Fully self-financing,supported by gavi,12382.0,4542.0,37.0,AMR,1 dose,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2021,UM,Fully self-financing,supported by gavi,35680.0,871.0,2.0,AMR,1 dose,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2022,H,mic_former_gavi,supported by gavi,35478.0,5809.0,16.0,AMR,1 dose,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2023,H,mic_former_gavi,supported by gavi,33076.0,13264.0,40.0,AMR,1 dose,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2024,H,mic_former_gavi,supported by gavi,26178.0,18567.0,71.0,AMR,1 dose,Yes,2011.0,School-based,9-16,Both sexes,32.7
GUY,Guyana,2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2011.0,School-based,9-16,Both sexes,32.7
HKG,"Hong Kong SAR, China",2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HKG,"Hong Kong SAR, China",2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
HND,Honduras,2008,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2009,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2010,LM,Least Poor,supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2011,LM,Graduating,supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2012,LM,Graduating,supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2013,LM,Graduating,supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2014,LM,Graduating,supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2015,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2016,LM,Fully self-financing,supported by gavi,104529.0,77622.0,74.0,AMR,1 dose,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2017,LM,Fully self-financing,supported by gavi,104093.0,73659.0,71.0,AMR,1 dose,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2018,LM,Fully self-financing,supported by gavi,103927.0,91712.0,88.0,AMR,1 dose,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2019,LM,Fully self-financing,supported by gavi,104150.0,78790.0,76.0,AMR,1 dose,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2020,LM,Fully self-financing,supported by gavi,104398.0,67615.0,65.0,AMR,1 dose,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2021,LM,Fully self-financing,supported by gavi,104403.0,73408.0,70.0,AMR,1 dose,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2022,LM,mic_former_gavi,supported by gavi,104331.0,74553.0,71.0,AMR,1 dose,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2023,LM,mic_former_gavi,supported by gavi,104524.0,77664.0,74.0,AMR,1 dose,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2024,LM,mic_former_gavi,supported by gavi,104710.0,75524.0,72.0,AMR,1 dose,Yes,2016.0,School-based,12-15,Female,17.9
HND,Honduras,2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,School-based,12-15,Female,17.9
HRV,Croatia,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2014,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2015,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2016,UM,N/A,not supported by gavi,38933.0,1161.0,3.0,EUR,2 doses (6 months),Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2017,H,N/A,not supported by gavi,19148.0,1352.0,7.0,EUR,2 doses (6 months),Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2018,H,N/A,not supported by gavi,18972.0,3017.0,16.0,EUR,2 doses (6 months),Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2019,H,N/A,not supported by gavi,19581.0,4834.0,25.0,EUR,2 doses (6 months),Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2020,H,N/A,not supported by gavi,19786.0,4000.0,20.0,EUR,2 doses (6 months),Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2021,H,N/A,not supported by gavi,19525.0,9096.0,47.0,EUR,2 doses (6 months),Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2022,H,N/A,not supported by gavi,20068.0,11066.0,55.0,EUR,2 doses (6 months),Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2023,H,N/A,not supported by gavi,20788.0,9964.0,48.0,EUR,2 doses (6 months),Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2024,H,N/A,not supported by gavi,20675.0,10874.0,53.0,EUR,2 doses (6 months),Yes,2016.0,School-based,14,Both sexes,13.0
HRV,Croatia,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,School-based,14,Both sexes,13.0
HTI,Haiti,2008,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2009,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2010,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2011,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2012,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2013,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2014,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2015,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2016,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2017,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2018,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2019,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2020,LM,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2021,LM,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2022,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2023,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2024,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HTI,Haiti,2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,14.7
HUN,Hungary,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2014,H,N/A,not supported by gavi,47065.0,35284.0,75.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2015,H,N/A,not supported by gavi,46524.0,33847.0,73.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2016,H,N/A,not supported by gavi,46048.0,33876.0,74.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2017,H,N/A,not supported by gavi,46903.0,33526.0,71.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2018,H,N/A,not supported by gavi,48691.0,36970.0,76.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2019,H,N/A,not supported by gavi,48842.0,41012.0,84.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2020,H,N/A,not supported by gavi,48474.0,39312.0,81.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2021,H,N/A,not supported by gavi,48272.0,36622.0,76.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2022,H,N/A,not supported by gavi,46151.0,35770.0,78.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2023,H,N/A,not supported by gavi,44218.0,33651.0,76.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2024,H,N/A,not supported by gavi,44275.0,34082.0,77.0,EUR,2 doses (6 months),Yes,2014.0,School-based,12,Both sexes,19.2
HUN,Hungary,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,12,Both sexes,19.2
IDN,Indonesia,2008,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2009,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2010,LM,Least Poor,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2011,LM,Graduating,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2012,LM,Graduating,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2013,LM,Graduating,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2014,LM,Graduating,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2015,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2016,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2017,LM,Fully self-financing,supported by gavi,2268865.0,100339.0,4.0,WPR,1 dose,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2018,LM,Fully self-financing,supported by gavi,2301210.0,114163.0,5.0,WPR,1 dose,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2019,UM,Fully self-financing,supported by gavi,2312035.0,22070.0,1.0,WPR,1 dose,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2020,LM,Fully self-financing,supported by gavi,2312930.0,120739.0,5.0,WPR,1 dose,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2021,LM,Fully self-financing,supported by gavi,2337738.0,132922.0,6.0,WPR,1 dose,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2022,UM,mic_former_gavi,supported by gavi,2384648.0,677600.0,28.0,WPR,1 dose,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2023,UM,mic_former_gavi,supported by gavi,2421177.0,1937802.0,80.0,WPR,1 dose,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2024,UM,mic_former_gavi,supported by gavi,2397151.0,1925570.0,80.0,WPR,1 dose,Yes,2017.0,School-based,11,Female,26.7
IDN,Indonesia,2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,School-based,11,Female,26.7
IMN,Isle of Man,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IMN,Isle of Man,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
IND,India,2008,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2009,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2010,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2011,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2012,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2013,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2014,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2017,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2018,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2019,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2020,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2021,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2022,LM,Fully self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2023,LM,Fully self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2024,LM,Fully self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IND,India,2025,N/A,Fully self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,18.9
IRL,Ireland,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2010,H,N/A,not supported by gavi,N/A,N/A,84.0,EUR,1 dose,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2011,H,N/A,not supported by gavi,N/A,N/A,84.0,EUR,1 dose,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2012,H,N/A,not supported by gavi,29620.0,26364.0,89.0,EUR,1 dose,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2013,H,N/A,not supported by gavi,29974.0,26869.0,90.0,EUR,1 dose,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2014,H,N/A,not supported by gavi,30515.0,27497.0,90.0,EUR,1 dose,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2015,H,N/A,not supported by gavi,31032.0,26154.0,84.0,EUR,1 dose,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2016,H,N/A,not supported by gavi,31188.0,17095.0,55.0,EUR,1 dose,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2017,H,N/A,not supported by gavi,31321.0,21615.0,69.0,EUR,1 dose,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2018,H,N/A,not supported by gavi,32001.0,24717.0,77.0,EUR,1 dose,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2019,H,N/A,not supported by gavi,33458.0,29213.0,87.0,EUR,1 dose,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2020,H,N/A,not supported by gavi,34907.0,21352.0,61.0,EUR,1 dose,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2021,H,N/A,not supported by gavi,35495.0,26594.0,75.0,EUR,1 dose,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2022,H,N/A,not supported by gavi,36028.0,29338.0,81.0,EUR,1 dose,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2023,H,N/A,not supported by gavi,36313.0,29478.0,81.0,EUR,1 dose,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2024,H,N/A,not supported by gavi,35666.0,26148.0,73.0,EUR,1 dose,Yes,2010.0,School-based,12,Both sexes,9.6
IRL,Ireland,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,12,Both sexes,9.6
IRN,"Iran, Islamic Rep.",2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,"Iran, Islamic Rep.",2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,"Iran, Islamic Rep.",2010,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,"Iran, Islamic Rep.",2011,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,"Iran, Islamic Rep.",2012,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,"Iran, Islamic Rep.",2013,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,"Iran, Islamic Rep.",2014,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,"Iran, Islamic Rep.",2015,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,"Iran, Islamic Rep.",2016,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,"Iran, Islamic Rep.",2017,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,"Iran, Islamic Rep.",2018,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,"Iran, Islamic Rep.",2019,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,"Iran, Islamic Rep.",2020,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,"Iran, Islamic Rep.",2021,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,"Iran, Islamic Rep.",2022,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,"Iran, Islamic Rep.",2023,UM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,"Iran, Islamic Rep.",2024,UM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRN,Iran,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,3.0
IRQ,Iraq,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2010,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2011,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2012,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2013,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2014,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2015,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2016,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2017,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2018,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2019,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2020,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2021,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2022,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2023,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2024,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
IRQ,Iraq,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.5
ISL,Iceland,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2011,H,N/A,not supported by gavi,4229.0,3854.0,91.0,EUR,2 doses (6 months),Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2012,H,N/A,not supported by gavi,2156.0,1944.0,90.0,EUR,2 doses (6 months),Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2013,H,N/A,not supported by gavi,2109.0,1833.0,87.0,EUR,2 doses (6 months),Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2014,H,N/A,not supported by gavi,2042.0,1897.0,93.0,EUR,2 doses (6 months),Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2015,H,N/A,not supported by gavi,2067.0,1834.0,89.0,EUR,2 doses (6 months),Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2016,H,N/A,not supported by gavi,2134.0,1990.0,93.0,EUR,2 doses (6 months),Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2017,H,N/A,not supported by gavi,2155.0,1931.0,90.0,EUR,2 doses (6 months),Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2018,H,N/A,not supported by gavi,2184.0,2057.0,94.0,EUR,2 doses (6 months),Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2019,H,N/A,not supported by gavi,2297.0,2164.0,94.0,EUR,2 doses (6 months),Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2020,H,N/A,not supported by gavi,2421.0,2206.0,91.0,EUR,2 doses (6 months),Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2021,H,N/A,not supported by gavi,2520.0,2157.0,86.0,EUR,2 doses (6 months),Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2022,H,N/A,not supported by gavi,2571.0,2165.0,84.0,EUR,2 doses (6 months),Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2023,H,N/A,not supported by gavi,2617.0,2356.0,90.0,EUR,2 doses (6 months),Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2024,H,N/A,not supported by gavi,N/A,N/A,93.0,EUR,2 doses (6 months),Yes,2011.0,School-based,12,Both sexes,11.1
ISL,Iceland,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2011.0,School-based,12,Both sexes,11.1
ISR,Israel,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2014,H,N/A,not supported by gavi,68083.0,37033.0,54.0,EUR,2 doses (6 months),Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2015,H,N/A,not supported by gavi,68654.0,43188.0,63.0,EUR,2 doses (6 months),Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2016,H,N/A,not supported by gavi,71178.0,43891.0,62.0,EUR,2 doses (6 months),Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2017,H,N/A,not supported by gavi,74328.0,38889.0,52.0,EUR,2 doses (6 months),Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2018,H,N/A,not supported by gavi,74066.0,40679.0,55.0,EUR,2 doses (6 months),Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2019,H,N/A,not supported by gavi,73869.0,42901.0,58.0,EUR,2 doses (6 months),Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2020,H,N/A,not supported by gavi,76039.0,46720.0,61.0,EUR,2 doses (6 months),Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2021,H,N/A,not supported by gavi,72146.0,47637.0,66.0,EUR,2 doses (6 months),Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2022,H,N/A,not supported by gavi,76124.0,42099.0,55.0,EUR,2 doses (6 months),Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2023,H,N/A,not supported by gavi,78344.0,40133.0,51.0,EUR,2 doses (6 months),Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2024,H,N/A,not supported by gavi,N/A,N/A,51.0,EUR,2 doses (6 months),Yes,2010.0,School-based,13,Both sexes,7.4
ISR,Israel,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,13,Both sexes,7.4
ITA,Italy,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2010,H,N/A,not supported by gavi,269728.0,150563.0,56.0,EUR,2 doses (6 months),Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2011,H,N/A,not supported by gavi,272924.0,183872.0,67.0,EUR,2 doses (6 months),Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2012,H,N/A,not supported by gavi,276942.0,193048.0,70.0,EUR,2 doses (6 months),Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2013,H,N/A,not supported by gavi,277856.0,189182.0,68.0,EUR,2 doses (6 months),Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2014,H,N/A,not supported by gavi,275032.0,177247.0,64.0,EUR,2 doses (6 months),Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2015,H,N/A,not supported by gavi,274663.0,182097.0,66.0,EUR,2 doses (6 months),Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2016,H,N/A,not supported by gavi,276565.0,180418.0,65.0,EUR,2 doses (6 months),Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2017,H,N/A,not supported by gavi,275849.0,176163.0,64.0,EUR,2 doses (6 months),Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2018,H,N/A,not supported by gavi,275075.0,170343.0,62.0,EUR,2 doses (6 months),Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2019,H,N/A,not supported by gavi,276115.0,171591.0,62.0,EUR,2 doses (6 months),Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2020,H,N/A,not supported by gavi,276888.0,124428.0,45.0,EUR,2 doses (6 months),Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2021,H,N/A,not supported by gavi,275983.0,145531.0,53.0,EUR,2 doses (6 months),Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2022,H,N/A,not supported by gavi,272273.0,158141.0,58.0,EUR,2 doses (6 months),Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2023,H,N/A,not supported by gavi,266599.0,167181.0,63.0,EUR,2 doses (6 months),Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2024,H,N/A,not supported by gavi,261095.0,173410.0,66.0,EUR,2 doses (6 months),Yes,2009.0,Varies by region/province,11,Both sexes,8.0
ITA,Italy,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,Varies by region/province,11,Both sexes,8.0
JAM,Jamaica,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2017,UM,N/A,not supported by gavi,23243.0,5391.0,23.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2018,UM,N/A,not supported by gavi,22788.0,5505.0,24.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2019,UM,N/A,not supported by gavi,22250.0,5140.0,23.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2020,UM,N/A,not supported by gavi,21666.0,1856.0,9.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2021,UM,N/A,not supported by gavi,21053.0,180.0,1.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2022,UM,N/A,not supported by gavi,20395.0,840.0,4.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2023,UM,N/A,not supported by gavi,19693.0,767.0,4.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2024,UM,N/A,not supported by gavi,19026.0,1401.0,7.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Both sexes,25.0
JAM,Jamaica,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,School-based,11-12,Both sexes,25.0
JOR,Jordan,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2010,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2011,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2012,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2013,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2014,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2015,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2016,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2017,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2018,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2019,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2020,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2021,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2022,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2023,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2024,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JOR,Jordan,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.6
JPN,Japan,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2013,H,N/A,not supported by gavi,583312.0,91015.0,16.0,WPR,2 doses (6 months),Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2014,H,N/A,not supported by gavi,582536.0,3300.0,1.0,WPR,2 doses (6 months),Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2015,H,N/A,not supported by gavi,575173.0,1885.0,0.0,WPR,2 doses (6 months),Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2016,H,N/A,not supported by gavi,566242.0,1007.0,0.0,WPR,2 doses (6 months),Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2017,H,N/A,not supported by gavi,557260.0,1581.0,0.0,WPR,2 doses (6 months),Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2018,H,N/A,not supported by gavi,544652.0,3362.0,1.0,WPR,2 doses (6 months),Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2019,H,N/A,not supported by gavi,540731.0,8551.0,2.0,WPR,2 doses (6 months),Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2020,H,N/A,not supported by gavi,544900.0,27538.0,5.0,WPR,2 doses (6 months),Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2021,H,N/A,not supported by gavi,543795.0,75641.0,14.0,WPR,2 doses (6 months),Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2022,H,N/A,not supported by gavi,538703.0,119327.0,22.0,WPR,2 doses (6 months),Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2023,H,N/A,not supported by gavi,531779.0,75641.0,14.0,WPR,2 doses (6 months),Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2024,H,N/A,not supported by gavi,525678.0,202908.0,39.0,WPR,2 doses (6 months),Yes,2013.0,Facility-based,13,Female,17.0
JPN,Japan,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,Facility-based,13,Female,17.0
KAZ,Kazakhstan,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2019,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2020,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2021,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2022,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2023,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2024,UM,N/A,not supported by gavi,190228.0,72380.0,38.0,EUR,2 doses (6 months),Yes,2024.0,School-based,11,Female,18.5
KAZ,Kazakhstan,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2024.0,School-based,11,Female,18.5
KEN,Kenya,2008,L,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2009,L,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2010,L,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2011,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2012,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2013,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2014,LM,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2015,LM,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2017,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2018,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2019,LM,Preparatory transition phase,supported by gavi,685583.0,170045.0,25.0,AFR,1 dose,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2020,LM,Preparatory transition phase,supported by gavi,691269.0,228698.0,33.0,AFR,1 dose,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2021,LM,Preparatory transition phase,supported by gavi,2984592.0,877907.0,29.0,AFR,1 dose,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2022,LM,Accelerated transition phase,supported by gavi,2137869.0,535717.0,25.0,AFR,1 dose,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2023,LM,Accelerated transition phase,supported by gavi,1605287.0,990835.0,62.0,AFR,1 dose,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2024,LM,Accelerated transition phase,supported by gavi,1444531.0,1134120.0,79.0,AFR,1 dose,Yes,2019.0,Facility-based,10-14,Female,20.7
KEN,Kenya,2025,N/A,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,Facility-based,10-14,Female,20.7
KGZ,Kyrgyz Republic,2008,L,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyz Republic,2009,L,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyz Republic,2010,L,Intermediate,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyz Republic,2011,L,Low income,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyz Republic,2012,L,Low income,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyz Republic,2013,LM,Low income,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyz Republic,2014,LM,Low income,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyz Republic,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyz Republic,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyz Republic,2017,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyz Republic,2018,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyz Republic,2019,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyz Republic,2020,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyz Republic,2021,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyz Republic,2022,LM,Preparatory transition phase,supported by gavi,269342.0,176150.0,65.0,EUR,1 dose,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyz Republic,2023,LM,Preparatory transition phase,supported by gavi,72014.0,50707.0,70.0,EUR,1 dose,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyz Republic,2024,LM,Preparatory transition phase,supported by gavi,73264.0,64798.0,88.0,EUR,1 dose,Yes,2022.0,School-based,N/A,Female,14.1
KGZ,Kyrgyzstan,2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,School-based,N/A,Female,14.1
KHM,Cambodia,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2010,L,Poorest,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2011,L,Low income,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2012,L,Low income,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2013,L,Low income,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2014,L,Low income,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2015,LM,Initial self-financing,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2016,LM,Initial self-financing,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2017,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2018,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2019,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2020,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2021,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2022,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2023,LM,Preparatory transition phase,supported by gavi,167203.0,145742.0,87.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2024,LM,Preparatory transition phase,supported by gavi,169639.0,144310.0,85.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,14.5
KHM,Cambodia,2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,N/A,9,Female,14.5
KIR,Kiribati,2008,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2009,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2010,LM,Least Poor,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2011,LM,Graduating,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2012,LM,Graduating,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2013,LM,Graduating,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2014,LM,Graduating,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2015,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2016,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2017,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2018,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2019,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2020,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2021,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2022,LM,mic_former_gavi,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2023,LM,mic_former_gavi,supported by gavi,8892.0,4849.0,55.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2024,LM,mic_former_gavi,supported by gavi,1498.0,1068.0,71.0,WPR,1 dose,Yes,2023.0,N/A,9,Female,N/A
KIR,Kiribati,2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,N/A,9,Female,N/A
KNA,St. Kitts and Nevis,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2014,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2015,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2016,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2017,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2018,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2019,H,N/A,not supported by gavi,386.0,349.0,90.0,AMR,1 dose,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2020,H,N/A,not supported by gavi,381.0,357.0,94.0,AMR,1 dose,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2021,H,N/A,not supported by gavi,355.0,263.0,74.0,AMR,1 dose,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2022,H,N/A,not supported by gavi,345.0,242.0,70.0,AMR,1 dose,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2023,H,N/A,not supported by gavi,379.0,244.0,64.0,AMR,1 dose,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2024,H,N/A,not supported by gavi,268.0,208.0,78.0,AMR,1 dose,Yes,2019.0,School-based,11,Both sexes,N/A
KNA,St. Kitts and Nevis,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,11,Both sexes,N/A
KOR,"Korea, Rep.",2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2010,H,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2011,H,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2012,H,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2013,H,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2014,H,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2015,H,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2016,H,N/A,not supported by gavi,456303.0,233689.0,51.0,WPR,2 doses (6 months),Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2017,H,N/A,not supported by gavi,316574.0,196084.0,62.0,WPR,2 doses (6 months),Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2018,H,N/A,not supported by gavi,247811.0,171899.0,69.0,WPR,2 doses (6 months),Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2019,H,N/A,not supported by gavi,233942.0,216761.0,93.0,WPR,2 doses (6 months),Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2020,H,N/A,not supported by gavi,221940.0,193188.0,87.0,WPR,2 doses (6 months),Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2021,H,N/A,not supported by gavi,227323.0,194033.0,85.0,WPR,2 doses (6 months),Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2022,H,N/A,not supported by gavi,219507.0,154273.0,70.0,WPR,2 doses (6 months),Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2023,H,N/A,not supported by gavi,218482.0,199402.0,91.0,WPR,2 doses (6 months),Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2024,H,N/A,not supported by gavi,226523.0,191693.0,85.0,WPR,2 doses (6 months),Yes,2016.0,Facility-based,12,Female,13.3
KOR,"Korea, Rep.",2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,Facility-based,12,Female,13.3
KWT,Kuwait,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2014,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2015,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2016,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2017,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2018,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2019,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2020,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2021,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2022,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,EMR,2 doses (6 months),Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,EMR,2 doses (6 months),Yes,2023.0,School-based,9-14,Both sexes,3.6
KWT,Kuwait,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,9-14,Both sexes,3.6
LAO,Lao PDR,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2010,LM,Poorest,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2011,LM,Low income,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2012,LM,Low income,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2013,LM,Intermediate,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2014,LM,Intermediate,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2017,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2018,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2019,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2020,LM,Accelerated transition phase,supported by gavi,368178.0,284056.0,77.0,WPR,1 dose,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2021,LM,Accelerated transition phase,supported by gavi,148251.0,43617.0,29.0,WPR,1 dose,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2022,LM,Accelerated transition phase,supported by gavi,165933.0,89687.0,54.0,WPR,1 dose,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2023,LM,Accelerated transition phase,supported by gavi,143295.0,84986.0,59.0,WPR,1 dose,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2024,LM,Accelerated transition phase,supported by gavi,129684.0,122798.0,95.0,WPR,1 dose,Yes,2020.0,School-based,10,Female,10.8
LAO,Lao PDR,2025,N/A,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2020.0,School-based,10,Female,10.8
LBN,Lebanon,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2010,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2011,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2012,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2013,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2014,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2015,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2016,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2017,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2018,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2019,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2020,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2021,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2022,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2023,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2024,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBN,Lebanon,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.3
LBR,Liberia,2008,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2009,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2010,L,Fragile,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2011,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2012,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2013,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2014,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2015,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2016,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2017,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2018,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2019,L,Initial self-financing,supported by gavi,67721.0,8970.0,13.0,AFR,1 dose,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2020,L,Initial self-financing,supported by gavi,68540.0,27167.0,40.0,AFR,1 dose,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2021,L,Initial self-financing,supported by gavi,70406.0,28325.0,40.0,AFR,1 dose,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2022,L,Initial self-financing,supported by gavi,71558.0,30117.0,42.0,AFR,1 dose,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2023,L,Initial self-financing,supported by gavi,71171.0,55899.0,79.0,AFR,1 dose,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2024,L,Initial self-financing,supported by gavi,71033.0,50101.0,71.0,AFR,1 dose,Yes,2019.0,mixed,9,Female,27.2
LBR,Liberia,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,mixed,9,Female,27.2
LBY,Libya,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,EMR,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,EMR,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,EMR,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2013,UM,N/A,not supported by gavi,N/A,N/A,N/A,EMR,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2014,UM,N/A,not supported by gavi,N/A,N/A,N/A,EMR,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2015,UM,N/A,not supported by gavi,N/A,N/A,N/A,EMR,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2016,UM,N/A,not supported by gavi,N/A,N/A,N/A,EMR,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2017,UM,N/A,not supported by gavi,N/A,N/A,N/A,EMR,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2018,UM,N/A,not supported by gavi,N/A,N/A,N/A,EMR,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2019,UM,N/A,not supported by gavi,N/A,N/A,N/A,EMR,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2020,UM,N/A,not supported by gavi,N/A,N/A,N/A,EMR,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2021,UM,N/A,not supported by gavi,N/A,N/A,N/A,EMR,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2022,UM,N/A,not supported by gavi,N/A,N/A,N/A,EMR,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2023,UM,N/A,not supported by gavi,123811.0,47953.0,39.0,EMR,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2024,UM,N/A,not supported by gavi,123811.0,62815.0,51.0,EMR,N/A,Yes,2013.0,N/A,12,Female,8.0
LBY,Libya,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,N/A,12,Female,8.0
LCA,St. Lucia,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,St. Lucia,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,St. Lucia,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,St. Lucia,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,St. Lucia,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,St. Lucia,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,St. Lucia,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,St. Lucia,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,St. Lucia,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,St. Lucia,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,St. Lucia,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,St. Lucia,2019,UM,N/A,not supported by gavi,1185.0,934.0,79.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,St. Lucia,2020,UM,N/A,not supported by gavi,1207.0,633.0,52.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,St. Lucia,2021,UM,N/A,not supported by gavi,1181.0,893.0,76.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,St. Lucia,2022,UM,mic_never_gavi,supported by gavi,1081.0,758.0,70.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,St. Lucia,2023,UM,mic_never_gavi,supported by gavi,1032.0,844.0,82.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,St. Lucia,2024,UM,mic_never_gavi,supported by gavi,1042.0,741.0,71.0,AMR,1 dose,Yes,2019.0,School-based,11-12,Both sexes,21.3
LCA,Saint Lucia,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,11-12,Both sexes,21.3
LIE,Liechtenstein,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LIE,Liechtenstein,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
LKA,Sri Lanka,2008,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2009,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2010,LM,Least Poor,supported by gavi,N/A,N/A,0.0,SEAR,2 doses (6 months),Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2011,LM,Graduating,supported by gavi,N/A,N/A,0.0,SEAR,2 doses (6 months),Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2012,LM,Graduating,supported by gavi,N/A,N/A,0.0,SEAR,2 doses (6 months),Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2013,LM,Graduating,supported by gavi,N/A,N/A,0.0,SEAR,2 doses (6 months),Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2014,LM,Graduating,supported by gavi,N/A,N/A,0.0,SEAR,2 doses (6 months),Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2015,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,SEAR,2 doses (6 months),Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2016,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,SEAR,2 doses (6 months),Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2017,LM,Fully self-financing,supported by gavi,180924.0,117071.0,65.0,SEAR,2 doses (6 months),Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2018,UM,Fully self-financing,supported by gavi,345831.0,300809.0,87.0,SEAR,2 doses (6 months),Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2019,LM,Fully self-financing,supported by gavi,173130.0,172054.0,99.0,SEAR,2 doses (6 months),Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2020,LM,Fully self-financing,supported by gavi,177970.0,119977.0,67.0,SEAR,2 doses (6 months),Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2021,LM,Fully self-financing,supported by gavi,176030.0,119761.0,68.0,SEAR,2 doses (6 months),Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2022,LM,mic_former_gavi,supported by gavi,174750.0,141262.0,81.0,SEAR,2 doses (6 months),Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2023,LM,mic_former_gavi,supported by gavi,174800.0,53840.0,31.0,SEAR,2 doses (6 months),Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2024,LM,mic_former_gavi,supported by gavi,335099.0,160511.0,48.0,SEAR,2 doses (6 months),Yes,2017.0,mixed,10-11,Female,14.0
LKA,Sri Lanka,2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,mixed,10-11,Female,14.0
LSO,Lesotho,2008,LM,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2009,LM,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2010,LM,Poorest,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2011,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2012,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2013,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2014,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2017,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2018,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2019,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2020,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2021,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2022,LM,Preparatory transition phase,supported by gavi,156476.0,93000.0,59.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2023,LM,Preparatory transition phase,supported by gavi,81295.0,47409.0,58.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2024,LM,Preparatory transition phase,supported by gavi,22942.0,16059.0,70.0,AFR,2 doses (6 months),Yes,2022.0,N/A,N/A,Female,54.3
LSO,Lesotho,2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,N/A,Female,54.3
LTU,Lithuania,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2014,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2015,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2016,H,N/A,not supported by gavi,12676.0,2337.0,18.0,EUR,2 doses (6 months),Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2017,H,N/A,not supported by gavi,15280.0,5275.0,35.0,EUR,2 doses (6 months),Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2018,H,N/A,not supported by gavi,12587.0,6966.0,55.0,EUR,2 doses (6 months),Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2019,H,N/A,not supported by gavi,14094.0,9071.0,64.0,EUR,2 doses (6 months),Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2020,H,N/A,not supported by gavi,15230.0,9388.0,62.0,EUR,2 doses (6 months),Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2021,H,N/A,not supported by gavi,15230.0,9222.0,61.0,EUR,2 doses (6 months),Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2022,H,N/A,not supported by gavi,15196.0,8786.0,58.0,EUR,2 doses (6 months),Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2023,H,N/A,not supported by gavi,14200.0,7754.0,55.0,EUR,2 doses (6 months),Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2024,H,N/A,not supported by gavi,14373.0,8262.0,57.0,EUR,2 doses (6 months),Yes,2016.0,Facility-based,11,Both sexes,20.7
LTU,Lithuania,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,Facility-based,11,Both sexes,20.7
LUX,Luxembourg,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2010,H,N/A,not supported by gavi,6507.0,1230.0,19.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2011,H,N/A,not supported by gavi,7068.0,1603.0,23.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2012,H,N/A,not supported by gavi,7019.0,1689.0,24.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2013,H,N/A,not supported by gavi,6904.0,1704.0,25.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2014,H,N/A,not supported by gavi,6860.0,1741.0,25.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2015,H,N/A,not supported by gavi,6688.0,2498.0,37.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2016,H,N/A,not supported by gavi,N/A,N/A,44.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2017,H,N/A,not supported by gavi,N/A,N/A,51.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2018,H,N/A,not supported by gavi,N/A,N/A,58.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2019,H,N/A,not supported by gavi,N/A,N/A,65.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2020,H,N/A,not supported by gavi,N/A,N/A,72.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2021,H,N/A,not supported by gavi,N/A,N/A,79.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2022,H,N/A,not supported by gavi,N/A,N/A,86.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2023,H,N/A,not supported by gavi,N/A,N/A,87.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2024,H,N/A,not supported by gavi,N/A,N/A,87.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LUX,Luxembourg,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,Facility-based,9-13,Both sexes,6.9
LVA,Latvia,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2010,UM,N/A,not supported by gavi,8541.0,4173.0,49.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2011,UM,N/A,not supported by gavi,8361.0,4905.0,59.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2012,H,N/A,not supported by gavi,8702.0,4811.0,55.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2013,H,N/A,not supported by gavi,9166.0,4944.0,54.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2014,H,N/A,not supported by gavi,8815.0,4189.0,48.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2015,H,N/A,not supported by gavi,8902.0,3973.0,45.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2016,H,N/A,not supported by gavi,9099.0,3593.0,39.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2017,H,N/A,not supported by gavi,8862.0,4060.0,46.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2018,H,N/A,not supported by gavi,9453.0,4430.0,47.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2019,H,N/A,not supported by gavi,9845.0,5189.0,53.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2020,H,N/A,not supported by gavi,10353.0,5867.0,57.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2021,H,N/A,not supported by gavi,10495.0,4229.0,40.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2022,H,N/A,not supported by gavi,10263.0,5706.0,56.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2023,H,N/A,not supported by gavi,9391.0,5708.0,61.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2024,H,N/A,not supported by gavi,9395.0,6020.0,64.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,23.9
LVA,Latvia,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,Facility-based,12,Both sexes,23.9
MAC,"Macao SAR, China",2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAC,"Macao SAR, China",2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2008,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2009,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAF,St. Martin (French part),2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MAR,Morocco,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2010,LM,N/A,not supported by gavi,N/A,N/A,0.0,EMR,1 dose,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2011,LM,N/A,not supported by gavi,N/A,N/A,0.0,EMR,1 dose,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2012,LM,N/A,not supported by gavi,N/A,N/A,0.0,EMR,1 dose,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2013,LM,N/A,not supported by gavi,N/A,N/A,0.0,EMR,1 dose,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2014,LM,N/A,not supported by gavi,N/A,N/A,0.0,EMR,1 dose,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2015,LM,N/A,not supported by gavi,N/A,N/A,0.0,EMR,1 dose,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2016,LM,N/A,not supported by gavi,N/A,N/A,0.0,EMR,1 dose,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2017,LM,N/A,not supported by gavi,N/A,N/A,0.0,EMR,1 dose,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2018,LM,N/A,not supported by gavi,N/A,N/A,0.0,EMR,1 dose,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2019,LM,N/A,not supported by gavi,N/A,N/A,0.0,EMR,1 dose,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2020,LM,N/A,not supported by gavi,N/A,N/A,0.0,EMR,1 dose,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2021,LM,N/A,not supported by gavi,N/A,N/A,0.0,EMR,1 dose,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2022,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,EMR,1 dose,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2023,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,EMR,1 dose,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2024,LM,mic_never_gavi,supported by gavi,324890.0,9267.0,3.0,EMR,1 dose,Yes,2022.0,N/A,N/A,Female,13.9
MAR,Morocco,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,N/A,Female,13.9
MCO,Monaco,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2024,H,N/A,not supported by gavi,N/A,N/A,16.0,EUR,2 doses (6 months),Yes,2006.0,Facility-based,11,Both sexes,N/A
MCO,Monaco,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2006.0,Facility-based,11,Both sexes,N/A
MDA,Moldova,2008,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,Moldova,2009,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,Moldova,2010,LM,Intermediate,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,Moldova,2011,LM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,Moldova,2012,LM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,Moldova,2013,LM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,Moldova,2014,LM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,Moldova,2015,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,Moldova,2016,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,Moldova,2017,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,Moldova,2018,LM,Fully self-financing,supported by gavi,38514.0,22591.0,0.0,EUR,2 doses (6 months),Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,Moldova,2019,LM,Fully self-financing,supported by gavi,19884.0,10936.0,55.0,EUR,2 doses (6 months),Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,Moldova,2020,UM,Fully self-financing,supported by gavi,19991.0,9556.0,48.0,EUR,2 doses (6 months),Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,Moldova,2021,UM,Fully self-financing,supported by gavi,20010.0,8458.0,42.0,EUR,2 doses (6 months),Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,Moldova,2022,UM,mic_former_gavi,supported by gavi,20624.0,8135.0,39.0,EUR,2 doses (6 months),Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,Moldova,2023,UM,mic_former_gavi,supported by gavi,21607.0,11212.0,52.0,EUR,2 doses (6 months),Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,Moldova,2024,UM,mic_former_gavi,supported by gavi,22418.0,11640.0,52.0,EUR,2 doses (6 months),Yes (Partial),2019.0,School-based,10,Female,20.1
MDA,"Moldova, Republic of",2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2019.0,School-based,10,Female,20.1
MDG,Madagascar,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2010,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2011,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2012,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2013,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2014,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2015,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2016,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2017,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2018,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2019,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2020,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2021,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2022,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2023,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2024,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDG,Madagascar,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,N/A,9-14,Female,27.8
MDV,Maldives,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2019,UM,N/A,not supported by gavi,15163.0,13596.0,90.0,SEAR,1 dose,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2020,UM,N/A,not supported by gavi,3558.0,2414.0,68.0,SEAR,1 dose,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2021,UM,N/A,not supported by gavi,3649.0,2096.0,57.0,SEAR,1 dose,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2022,UM,mic_never_gavi,supported by gavi,3653.0,3026.0,83.0,SEAR,1 dose,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2023,UM,mic_never_gavi,supported by gavi,3583.0,2137.0,60.0,SEAR,1 dose,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2024,UM,mic_never_gavi,supported by gavi,3494.0,2616.0,75.0,SEAR,1 dose,Yes,2019.0,School-based,10,Female,25.1
MDV,Maldives,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,10,Female,25.1
MEX,Mexico,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2012,UM,N/A,not supported by gavi,1124198.0,890372.0,79.0,AMR,1 dose,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2013,UM,N/A,not supported by gavi,1120841.0,1209060.0,99.0,AMR,1 dose,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2014,UM,N/A,not supported by gavi,1114931.0,1118386.0,99.0,AMR,1 dose,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2015,UM,N/A,not supported by gavi,1110036.0,1090430.0,98.0,AMR,1 dose,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2016,UM,N/A,not supported by gavi,1102027.0,1137134.0,99.0,AMR,1 dose,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2017,UM,N/A,not supported by gavi,1098676.0,1098616.0,99.0,AMR,1 dose,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2018,UM,N/A,not supported by gavi,1095472.0,1090334.0,99.0,AMR,1 dose,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2019,UM,N/A,not supported by gavi,1092980.0,483135.0,44.0,AMR,1 dose,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2020,UM,N/A,not supported by gavi,1089876.0,217105.0,20.0,AMR,1 dose,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2021,UM,N/A,not supported by gavi,1086636.0,13512.0,1.0,AMR,1 dose,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2022,UM,N/A,not supported by gavi,2176714.0,1749441.0,80.0,AMR,1 dose,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2023,UM,N/A,not supported by gavi,3325078.0,2720014.0,82.0,AMR,1 dose,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2024,UM,N/A,not supported by gavi,1110733.0,906764.0,82.0,AMR,1 dose,Yes,2012.0,School-based,9-11,Both sexes,15.4
MEX,Mexico,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2012.0,School-based,9-11,Both sexes,15.4
MHL,Marshall Islands,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2010,LM,N/A,not supported by gavi,636.0,235.0,37.0,WPR,2 doses (6 months),Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2011,LM,N/A,not supported by gavi,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2012,UM,N/A,not supported by gavi,605.0,154.0,25.0,WPR,2 doses (6 months),Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2013,UM,N/A,not supported by gavi,568.0,89.0,16.0,WPR,2 doses (6 months),Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2014,UM,N/A,not supported by gavi,563.0,367.0,65.0,WPR,2 doses (6 months),Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2015,UM,N/A,not supported by gavi,585.0,249.0,43.0,WPR,2 doses (6 months),Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2016,UM,N/A,not supported by gavi,599.0,725.0,99.0,WPR,2 doses (6 months),Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2017,UM,N/A,not supported by gavi,585.0,175.0,30.0,WPR,2 doses (6 months),Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2018,UM,N/A,not supported by gavi,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2019,UM,N/A,not supported by gavi,618.0,564.0,91.0,WPR,2 doses (6 months),Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2020,UM,N/A,not supported by gavi,619.0,517.0,84.0,WPR,2 doses (6 months),Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2021,UM,N/A,not supported by gavi,614.0,461.0,75.0,WPR,2 doses (6 months),Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2022,UM,mic_never_gavi,supported by gavi,471.0,311.0,66.0,WPR,2 doses (6 months),Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2023,UM,mic_never_gavi,supported by gavi,559.0,268.0,48.0,WPR,2 doses (6 months),Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2024,UM,mic_never_gavi,supported by gavi,486.0,338.0,70.0,WPR,2 doses (6 months),Yes,2009.0,mixed,11,Female,N/A
MHL,Marshall Islands,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,mixed,11,Female,N/A
MKD,North Macedonia,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2010,UM,N/A,not supported by gavi,14037.0,6100.0,43.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2011,UM,N/A,not supported by gavi,13575.0,6681.0,49.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2012,UM,N/A,not supported by gavi,13243.0,5259.0,40.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2013,UM,N/A,not supported by gavi,13124.0,6342.0,48.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2014,UM,N/A,not supported by gavi,12986.0,4870.0,38.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2015,UM,N/A,not supported by gavi,12562.0,5755.0,46.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2016,UM,N/A,not supported by gavi,11526.0,5117.0,44.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2017,UM,N/A,not supported by gavi,10609.0,5004.0,47.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2018,UM,N/A,not supported by gavi,10412.0,5051.0,49.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2019,UM,N/A,not supported by gavi,N/A,N/A,47.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2020,UM,N/A,not supported by gavi,10386.0,4802.0,46.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2021,UM,N/A,not supported by gavi,10672.0,3404.0,32.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2022,UM,N/A,not supported by gavi,10859.0,5101.0,47.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2023,UM,N/A,not supported by gavi,10698.0,5179.0,48.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2024,UM,N/A,not supported by gavi,10604.0,6165.0,58.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,10.3
MKD,North Macedonia,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,School-based,12,Both sexes,10.3
MLI,Mali,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2010,L,Poorest,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2011,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2012,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2013,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2014,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2015,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2016,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2017,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2018,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2019,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2020,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2021,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2022,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2023,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2024,L,Initial self-financing,supported by gavi,343798.0,50563.0,15.0,AFR,1 dose,Yes,2024.0,mixed,10,Female,22.8
MLI,Mali,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2024.0,mixed,10,Female,22.8
MLT,Malta,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2013,H,N/A,not supported by gavi,4299.0,3776.0,88.0,EUR,2 doses (6 months),Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2014,H,N/A,not supported by gavi,1944.0,1717.0,88.0,EUR,2 doses (6 months),Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2015,H,N/A,not supported by gavi,2014.0,1831.0,91.0,EUR,2 doses (6 months),Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2016,H,N/A,not supported by gavi,2030.0,1740.0,86.0,EUR,2 doses (6 months),Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2017,H,N/A,not supported by gavi,1996.0,1734.0,87.0,EUR,2 doses (6 months),Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2018,H,N/A,not supported by gavi,1999.0,1744.0,87.0,EUR,2 doses (6 months),Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2019,H,N/A,not supported by gavi,1999.0,1689.0,84.0,EUR,2 doses (6 months),Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2020,H,N/A,not supported by gavi,2110.0,1847.0,88.0,EUR,2 doses (6 months),Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2021,H,N/A,not supported by gavi,2236.0,1957.0,88.0,EUR,2 doses (6 months),Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2022,H,N/A,not supported by gavi,2253.0,1921.0,85.0,EUR,2 doses (6 months),Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2023,H,N/A,not supported by gavi,2313.0,1777.0,77.0,EUR,2 doses (6 months),Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2024,H,N/A,not supported by gavi,2361.0,2037.0,86.0,EUR,2 doses (6 months),Yes,2013.0,Facility-based,12,Both sexes,5.9
MLT,Malta,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,Facility-based,12,Both sexes,5.9
MMR,Myanmar,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2010,L,Poorest,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2011,L,Low income,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2012,L,Low income,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2013,L,Low income,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2014,LM,Low income,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2015,LM,Initial self-financing,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2017,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2018,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2019,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2020,LM,Preparatory transition phase,supported by gavi,515711.0,456831.0,89.0,SEAR,1 dose,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2021,LM,Preparatory transition phase,supported by gavi,426522.0,0.0,0.0,SEAR,1 dose,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2022,LM,Preparatory transition phase,supported by gavi,426526.0,34772.0,8.0,SEAR,1 dose,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2023,LM,Preparatory transition phase,supported by gavi,1280029.0,967584.0,76.0,SEAR,1 dose,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2024,LM,Preparatory transition phase,supported by gavi,431205.0,359591.0,83.0,SEAR,1 dose,Yes,2020.0,School-based,9,Female,24.6
MMR,Myanmar,2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2020.0,School-based,9,Female,24.6
MNE,Montenegro,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2019,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2020,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2021,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2022,UM,N/A,not supported by gavi,3696.0,1056.0,29.0,EUR,1 dose,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2023,UM,N/A,not supported by gavi,22339.0,3991.0,18.0,EUR,1 dose,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2024,UM,N/A,not supported by gavi,19199.0,984.0,5.0,EUR,1 dose,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNE,Montenegro,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,Facility-based,9-14,Both sexes,18.3
MNG,Mongolia,2008,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2009,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2010,LM,Intermediate,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2011,LM,Graduating,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2012,LM,Graduating,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2013,LM,Graduating,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2014,UM,Graduating,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2015,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2016,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2017,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2018,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2019,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2020,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2021,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2022,LM,mic_former_gavi,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2023,UM,mic_former_gavi,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2024,UM,mic_former_gavi,supported by gavi,38526.0,9651.0,25.0,WPR,1 dose,Yes,2024.0,School-based,11,Both sexes,21.0
MNG,Mongolia,2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2024.0,School-based,11,Both sexes,21.0
MNP,Northern Mariana Islands,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MNP,Northern Mariana Islands,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
MOZ,Mozambique,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2010,L,Poorest,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2011,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2012,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2013,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2014,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2015,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2016,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2017,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2018,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2019,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2020,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2021,L,Initial self-financing,supported by gavi,453578.0,251124.0,55.0,AFR,1 dose,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2022,L,Initial self-financing,supported by gavi,513225.0,480250.0,94.0,AFR,1 dose,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2023,L,Initial self-financing,supported by gavi,472743.0,323162.0,68.0,AFR,1 dose,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2024,L,Initial self-financing,supported by gavi,689327.0,615889.0,89.0,AFR,1 dose,Yes,2021.0,School-based,9,Female,32.1
MOZ,Mozambique,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,School-based,9,Female,32.1
MRT,Mauritania,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2010,LM,Poorest,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2011,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2012,LM,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2013,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2014,LM,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2017,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2018,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2019,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2020,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2021,LM,Preparatory transition phase,supported by gavi,364738.0,129448.0,35.0,AFR,1 dose,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2022,LM,Preparatory transition phase,supported by gavi,375129.0,74825.0,20.0,AFR,1 dose,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2023,LM,Preparatory transition phase,supported by gavi,67903.0,10949.0,16.0,AFR,1 dose,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2024,LM,Preparatory transition phase,supported by gavi,126351.0,64894.0,51.0,AFR,1 dose,Yes,2021.0,mixed,9,Female,19.2
MRT,Mauritania,2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,mixed,9,Female,19.2
MUS,Mauritius,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2016,UM,N/A,not supported by gavi,8419.0,6334.0,75.0,AFR,2 doses (6 months),Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2017,UM,N/A,not supported by gavi,8127.0,7151.0,88.0,AFR,2 doses (6 months),Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2018,UM,N/A,not supported by gavi,7770.0,6546.0,84.0,AFR,2 doses (6 months),Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2019,H,N/A,not supported by gavi,7441.0,6192.0,83.0,AFR,2 doses (6 months),Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2020,UM,N/A,not supported by gavi,7149.0,5881.0,82.0,AFR,2 doses (6 months),Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2021,UM,N/A,not supported by gavi,6862.0,5388.0,79.0,AFR,2 doses (6 months),Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2022,UM,N/A,not supported by gavi,6601.0,2758.0,42.0,AFR,2 doses (6 months),Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2023,UM,N/A,not supported by gavi,6391.0,3823.0,60.0,AFR,2 doses (6 months),Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2024,UM,N/A,not supported by gavi,7400.0,6784.0,92.0,AFR,2 doses (6 months),Yes,2016.0,School-based,9,Both sexes,21.0
MUS,Mauritius,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,School-based,9,Both sexes,21.0
MWI,Malawi,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2010,L,Poorest,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2011,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2012,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2013,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2014,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2015,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2016,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2017,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2018,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2019,L,Initial self-financing,supported by gavi,277332.0,233229.0,84.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2020,L,Initial self-financing,supported by gavi,279834.0,224839.0,80.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2021,L,Initial self-financing,supported by gavi,281846.0,36402.0,13.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2022,L,Initial self-financing,supported by gavi,284014.0,37296.0,13.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2023,L,Initial self-financing,supported by gavi,285261.0,192614.0,68.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2024,L,Initial self-financing,supported by gavi,965874.0,519189.0,54.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,46.0
MWI,Malawi,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9,Female,46.0
MYS,Malaysia,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2010,UM,N/A,not supported by gavi,265477.0,128939.0,49.0,WPR,1 dose,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2011,UM,N/A,not supported by gavi,265536.0,228796.0,86.0,WPR,1 dose,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2012,UM,N/A,not supported by gavi,267860.0,232281.0,87.0,WPR,1 dose,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2013,UM,N/A,not supported by gavi,269860.0,243530.0,90.0,WPR,1 dose,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2014,UM,N/A,not supported by gavi,270695.0,226051.0,84.0,WPR,1 dose,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2015,UM,N/A,not supported by gavi,270849.0,220749.0,82.0,WPR,1 dose,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2016,UM,N/A,not supported by gavi,272298.0,214904.0,79.0,WPR,1 dose,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2017,UM,N/A,not supported by gavi,274901.0,243530.0,89.0,WPR,1 dose,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2018,UM,N/A,not supported by gavi,271985.0,208419.0,77.0,WPR,1 dose,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2019,UM,N/A,not supported by gavi,263077.0,208500.0,79.0,WPR,1 dose,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2020,UM,N/A,not supported by gavi,259740.0,209279.0,81.0,WPR,1 dose,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2021,UM,N/A,not supported by gavi,260027.0,34933.0,13.0,WPR,1 dose,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2022,UM,N/A,not supported by gavi,260940.0,94348.0,36.0,WPR,1 dose,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2023,UM,N/A,not supported by gavi,264515.0,160139.0,61.0,WPR,1 dose,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2024,UM,N/A,not supported by gavi,264127.0,206647.0,78.0,WPR,1 dose,Yes,2010.0,School-based,13,Female,11.9
MYS,Malaysia,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,13,Female,11.9
NAM,Namibia,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2010,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2011,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2012,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2013,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2014,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2015,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2016,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2017,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2018,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2019,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2020,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2021,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2022,UM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2023,UM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2024,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NAM,Namibia,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,Facility based,9-14,Female,25.8
NCL,New Caledonia,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NCL,New Caledonia,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,18.6
NER,Niger,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2010,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2011,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2012,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2013,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2014,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2015,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2016,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2017,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2018,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2019,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2020,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2021,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2022,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2023,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2024,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NER,Niger,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,4.8
NGA,Nigeria,2008,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2009,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2010,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2011,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2012,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2013,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2014,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2017,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2018,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2019,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2020,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2021,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2022,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2023,LM,Accelerated transition phase,supported by gavi,17442568.0,4631159.0,27.0,AFR,1 dose,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2024,LM,Accelerated transition phase,supported by gavi,13916556.0,8290701.0,60.0,AFR,1 dose,Yes,2023.0,mixed,9-14,Female,12.8
NGA,Nigeria,2025,N/A,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,mixed,9-14,Female,12.8
NIC,Nicaragua,2008,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2009,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2010,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2011,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2012,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2013,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2014,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2016,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2017,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2018,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2019,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2020,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2021,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2022,LM,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2023,LM,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2024,LM,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIC,Nicaragua,2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,12-14,Female,21.0
NIU,NIUE,2010,N/A,N/A,N/A,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2019.0,School-based,12,Both sexes,N/A
NIU,NIUE,2011,N/A,N/A,N/A,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2019.0,School-based,12,Both sexes,N/A
NIU,NIUE,2012,N/A,N/A,N/A,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2019.0,School-based,12,Both sexes,N/A
NIU,NIUE,2013,N/A,N/A,N/A,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2019.0,School-based,12,Both sexes,N/A
NIU,NIUE,2014,N/A,N/A,N/A,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2019.0,School-based,12,Both sexes,N/A
NIU,NIUE,2015,N/A,N/A,N/A,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2019.0,School-based,12,Both sexes,N/A
NIU,NIUE,2016,N/A,N/A,N/A,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2019.0,School-based,12,Both sexes,N/A
NIU,NIUE,2017,N/A,N/A,N/A,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2019.0,School-based,12,Both sexes,N/A
NIU,NIUE,2018,N/A,N/A,N/A,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2019.0,School-based,12,Both sexes,N/A
NIU,NIUE,2019,N/A,N/A,N/A,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2019.0,School-based,12,Both sexes,N/A
NIU,NIUE,2020,N/A,N/A,N/A,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2019.0,School-based,12,Both sexes,N/A
NIU,NIUE,2021,N/A,N/A,N/A,33.0,25.0,76.0,WPR,2 doses (6 months),Yes,2019.0,School-based,12,Both sexes,N/A
NIU,NIUE,2022,N/A,N/A,N/A,23.0,23.0,99.0,WPR,2 doses (6 months),Yes,2019.0,School-based,12,Both sexes,N/A
NIU,NIUE,2023,N/A,N/A,N/A,19.0,19.0,99.0,WPR,2 doses (6 months),Yes,2019.0,School-based,12,Both sexes,N/A
NIU,NIUE,2024,N/A,N/A,N/A,N/A,N/A,99.0,WPR,2 doses (6 months),Yes,2019.0,School-based,12,Both sexes,N/A
NLD,Netherlands,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2010,H,N/A,not supported by gavi,384934.0,221315.0,57.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2011,H,N/A,not supported by gavi,95911.0,59036.0,62.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2012,H,N/A,not supported by gavi,98354.0,62838.0,64.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2013,H,N/A,not supported by gavi,99214.0,64563.0,65.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2014,H,N/A,not supported by gavi,102189.0,68207.0,67.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2015,H,N/A,not supported by gavi,100139.0,66293.0,66.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2016,H,N/A,not supported by gavi,99479.0,59835.0,60.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2017,H,N/A,not supported by gavi,99507.0,52743.0,53.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2018,H,N/A,not supported by gavi,96895.0,50675.0,52.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2019,H,N/A,not supported by gavi,94365.0,59021.0,63.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2020,H,N/A,not supported by gavi,93684.0,68123.0,73.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2021,H,N/A,not supported by gavi,N/A,N/A,66.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2022,H,N/A,not supported by gavi,N/A,N/A,64.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2023,H,N/A,not supported by gavi,N/A,N/A,60.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2024,H,N/A,not supported by gavi,N/A,N/A,63.0,EUR,2 doses (6 months),Yes,2010.0,Facility-based,12,Both sexes,8.8
NLD,Netherlands,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,Facility-based,12,Both sexes,8.8
NOR,Norway,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2010,H,N/A,not supported by gavi,30491.0,22000.0,72.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2011,H,N/A,not supported by gavi,30410.0,23500.0,77.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2012,H,N/A,not supported by gavi,30649.0,23905.0,78.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2013,H,N/A,not supported by gavi,30261.0,25323.0,84.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2014,H,N/A,not supported by gavi,29627.0,25767.0,87.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2015,H,N/A,not supported by gavi,29798.0,26244.0,88.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2016,H,N/A,not supported by gavi,30340.0,27603.0,91.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2017,H,N/A,not supported by gavi,30579.0,27832.0,91.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2018,H,N/A,not supported by gavi,30994.0,29093.0,94.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2019,H,N/A,not supported by gavi,31345.0,29048.0,93.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2020,H,N/A,not supported by gavi,31701.0,29872.0,94.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2021,H,N/A,not supported by gavi,32358.0,29329.0,91.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2022,H,N/A,not supported by gavi,32630.0,31038.0,95.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2023,H,N/A,not supported by gavi,32132.0,29507.0,92.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2024,H,N/A,not supported by gavi,31651.0,29551.0,93.0,EUR,2 doses (6 months),Yes,2009.0,School-based,12,Both sexes,13.8
NOR,Norway,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,School-based,12,Both sexes,13.8
NPL,Nepal,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2010,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2011,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2012,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2013,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2014,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2015,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2016,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2017,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2018,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2019,LM,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2020,LM,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2021,LM,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2022,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2023,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2024,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NPL,Nepal,2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10,Female,13.4
NRU,Nauru,2008,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2009,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2010,N/A,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2011,N/A,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2012,N/A,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2013,N/A,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2014,N/A,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2015,H,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2019,H,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2020,H,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2024,H,N/A,not supported by gavi,594.0,139.0,23.0,WPR,2 doses (6 months),Yes,2021.0,N/A,11,Female,N/A
NRU,Nauru,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,N/A,11,Female,N/A
NZL,New Zealand,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2010,H,N/A,not supported by gavi,29320.0,14331.0,49.0,WPR,2 doses (6 months),Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2011,H,N/A,not supported by gavi,29292.0,15286.0,52.0,WPR,2 doses (6 months),Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2012,H,N/A,not supported by gavi,29542.0,15632.0,53.0,WPR,2 doses (6 months),Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2013,H,N/A,not supported by gavi,29340.0,16398.0,56.0,WPR,2 doses (6 months),Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2014,H,N/A,not supported by gavi,28700.0,16174.0,56.0,WPR,2 doses (6 months),Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2015,H,N/A,not supported by gavi,N/A,N/A,56.0,WPR,2 doses (6 months),Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2016,H,N/A,not supported by gavi,28925.0,16375.0,57.0,WPR,2 doses (6 months),Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2017,H,N/A,not supported by gavi,29393.0,19098.0,65.0,WPR,2 doses (6 months),Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2018,H,N/A,not supported by gavi,30241.0,18936.0,63.0,WPR,2 doses (6 months),Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2019,H,N/A,not supported by gavi,31533.0,22170.0,70.0,WPR,2 doses (6 months),Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2020,H,N/A,not supported by gavi,32456.0,22334.0,69.0,WPR,2 doses (6 months),Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2021,H,N/A,not supported by gavi,32761.0,21670.0,66.0,WPR,2 doses (6 months),Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2022,H,N/A,not supported by gavi,34849.0,24517.0,70.0,WPR,2 doses (6 months),Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2023,H,N/A,not supported by gavi,32999.0,22982.0,70.0,WPR,2 doses (6 months),Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2024,H,N/A,not supported by gavi,32781.0,17324.0,53.0,WPR,2 doses (6 months),Yes,2008.0,mixed,11,Both sexes,6.0
NZL,New Zealand,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,mixed,11,Both sexes,6.0
OMN,Oman,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
OMN,Oman,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Both sexes,4.9
PAK,Pakistan,2008,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2009,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2010,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2011,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2012,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2013,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2014,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2017,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2018,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2019,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2020,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2021,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2022,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2023,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2024,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAK,Pakistan,2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2025.0,mixed,9-14,Female,4.3
PAN,Panama,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2010,UM,N/A,not supported by gavi,33666.0,34561.0,99.0,AMR,2 doses (6 months),Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2011,UM,N/A,not supported by gavi,33929.0,30817.0,91.0,AMR,2 doses (6 months),Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2012,UM,N/A,not supported by gavi,34191.0,33750.0,99.0,AMR,2 doses (6 months),Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2013,UM,N/A,not supported by gavi,34465.0,29001.0,84.0,AMR,2 doses (6 months),Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2014,UM,N/A,not supported by gavi,34888.0,29802.0,85.0,AMR,2 doses (6 months),Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2015,UM,N/A,not supported by gavi,35166.0,30174.0,86.0,AMR,2 doses (6 months),Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2016,UM,N/A,not supported by gavi,35264.0,38430.0,99.0,AMR,2 doses (6 months),Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2017,H,N/A,not supported by gavi,35555.0,29101.0,82.0,AMR,2 doses (6 months),Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2018,H,N/A,not supported by gavi,35965.0,31137.0,87.0,AMR,2 doses (6 months),Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2019,H,N/A,not supported by gavi,36310.0,31003.0,85.0,AMR,2 doses (6 months),Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2020,UM,N/A,not supported by gavi,36612.0,24472.0,67.0,AMR,2 doses (6 months),Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2021,H,N/A,not supported by gavi,37115.0,27865.0,75.0,AMR,2 doses (6 months),Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2022,H,N/A,not supported by gavi,37557.0,35821.0,95.0,AMR,2 doses (6 months),Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2023,H,N/A,not supported by gavi,37703.0,32048.0,85.0,AMR,2 doses (6 months),Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2024,H,N/A,not supported by gavi,37824.0,26943.0,71.0,AMR,2 doses (6 months),Yes,2008.0,mixed,10,Both sexes,16.7
PAN,Panama,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,mixed,10,Both sexes,16.7
PER,Peru,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2012,UM,N/A,not supported by gavi,270024.0,321.0,0.0,AMR,1 dose,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2013,UM,N/A,not supported by gavi,271424.0,521.0,0.0,AMR,1 dose,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2014,UM,N/A,not supported by gavi,276228.0,148050.0,0.0,AMR,1 dose,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2015,UM,N/A,not supported by gavi,280882.0,203661.0,73.0,AMR,1 dose,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2016,UM,N/A,not supported by gavi,565357.0,374841.0,66.0,AMR,1 dose,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2017,UM,N/A,not supported by gavi,285818.0,141193.0,49.0,AMR,1 dose,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2018,UM,N/A,not supported by gavi,285058.0,153344.0,54.0,AMR,1 dose,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2019,UM,N/A,not supported by gavi,282936.0,188189.0,67.0,AMR,1 dose,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2020,UM,N/A,not supported by gavi,279767.0,136429.0,49.0,AMR,1 dose,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2021,UM,N/A,not supported by gavi,278527.0,106793.0,38.0,AMR,1 dose,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2022,UM,N/A,not supported by gavi,276833.0,196837.0,71.0,AMR,1 dose,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2023,UM,N/A,not supported by gavi,273321.0,166145.0,61.0,AMR,1 dose,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2024,UM,N/A,not supported by gavi,270862.0,262585.0,97.0,AMR,1 dose,Yes,2015.0,School-based,10,Both sexes,28.4
PER,Peru,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2015.0,School-based,10,Both sexes,28.4
PHL,Philippines,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2010,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2011,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2012,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2013,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2014,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2015,LM,N/A,not supported by gavi,1115759.0,292480.0,0.0,WPR,2 doses (6 months),Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2016,LM,N/A,not supported by gavi,1132122.0,358870.0,32.0,WPR,2 doses (6 months),Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2017,LM,N/A,not supported by gavi,1147639.0,293046.0,26.0,WPR,2 doses (6 months),Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2018,LM,N/A,not supported by gavi,1160621.0,155411.0,13.0,WPR,2 doses (6 months),Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2019,LM,N/A,not supported by gavi,1159110.0,253224.0,22.0,WPR,2 doses (6 months),Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2020,LM,N/A,not supported by gavi,1167093.0,250636.0,21.0,WPR,2 doses (6 months),Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2021,LM,N/A,not supported by gavi,1171968.0,43960.0,4.0,WPR,2 doses (6 months),Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2022,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,WPR,2 doses (6 months),Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2023,LM,mic_never_gavi,supported by gavi,1139235.0,292633.0,26.0,WPR,2 doses (6 months),Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2024,LM,mic_never_gavi,supported by gavi,1123627.0,566106.0,50.0,WPR,2 doses (6 months),Yes (Partial),2016.0,School-based,9-14,Female,15.3
PHL,Philippines,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes (Partial),2016.0,School-based,9-14,Female,15.3
PLW,Palau,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2010,UM,N/A,not supported by gavi,219.0,49.0,22.0,WPR,2 doses (6 months),Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2011,UM,N/A,not supported by gavi,269.0,92.0,34.0,WPR,2 doses (6 months),Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2012,UM,N/A,not supported by gavi,324.0,131.0,40.0,WPR,2 doses (6 months),Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2013,UM,N/A,not supported by gavi,N/A,N/A,10.0,WPR,2 doses (6 months),Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2014,UM,N/A,not supported by gavi,N/A,N/A,19.0,WPR,2 doses (6 months),Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2015,UM,N/A,not supported by gavi,N/A,N/A,30.0,WPR,2 doses (6 months),Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2016,H,N/A,not supported by gavi,N/A,N/A,42.0,WPR,2 doses (6 months),Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2017,H,N/A,not supported by gavi,N/A,N/A,54.0,WPR,2 doses (6 months),Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2018,H,N/A,not supported by gavi,N/A,N/A,63.0,WPR,2 doses (6 months),Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2019,H,N/A,not supported by gavi,N/A,N/A,70.0,WPR,2 doses (6 months),Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2020,H,N/A,not supported by gavi,N/A,N/A,72.0,WPR,2 doses (6 months),Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2021,UM,N/A,not supported by gavi,N/A,N/A,69.0,WPR,2 doses (6 months),Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2022,UM,N/A,not supported by gavi,N/A,N/A,64.0,WPR,2 doses (6 months),Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2023,H,N/A,not supported by gavi,N/A,N/A,58.0,WPR,2 doses (6 months),Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2024,H,N/A,not supported by gavi,N/A,N/A,58.0,WPR,2 doses (6 months),Yes,2008.0,School-based,N/A,Female,N/A
PLW,Palau,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,School-based,N/A,Female,N/A
PNG,Papua New Guinea,2008,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2009,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2010,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2011,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2012,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2013,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2014,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2016,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2017,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2018,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2019,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2020,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2021,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2022,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2023,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2024,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
PNG,Papua New Guinea,2025,N/A,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.2
POL,Poland,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2014,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2015,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2016,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2017,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2018,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2019,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2020,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2021,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2022,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2023,H,N/A,not supported by gavi,620218.0,99602.0,16.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2024,H,N/A,not supported by gavi,1103745.0,114054.0,10.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,20.6
POL,Poland,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,Facility-based,11-14,Both sexes,20.6
PRI,Puerto Rico (U.S.),2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRI,Puerto Rico (U.S.),2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,14.2
PRK,"Korea, Dem. Rep.",2008,L,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,"Korea, Dem. Rep.",2009,L,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,"Korea, Dem. Rep.",2010,L,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,"Korea, Dem. Rep.",2011,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,"Korea, Dem. Rep.",2012,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,"Korea, Dem. Rep.",2013,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,"Korea, Dem. Rep.",2014,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,"Korea, Dem. Rep.",2015,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,"Korea, Dem. Rep.",2016,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,"Korea, Dem. Rep.",2017,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,"Korea, Dem. Rep.",2018,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,"Korea, Dem. Rep.",2019,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,"Korea, Dem. Rep.",2020,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,"Korea, Dem. Rep.",2021,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,"Korea, Dem. Rep.",2022,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,"Korea, Dem. Rep.",2023,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,"Korea, Dem. Rep.",2024,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRK,Korea DPR,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,16.2
PRT,Portugal,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2010,H,N/A,not supported by gavi,56462.0,51371.0,91.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2011,H,N/A,not supported by gavi,57870.0,53026.0,92.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2012,H,N/A,not supported by gavi,57334.0,53308.0,93.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2013,H,N/A,not supported by gavi,58025.0,54478.0,94.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2014,H,N/A,not supported by gavi,58658.0,54668.0,93.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2015,H,N/A,not supported by gavi,54597.0,50450.0,92.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2016,H,N/A,not supported by gavi,54527.0,49950.0,92.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2017,H,N/A,not supported by gavi,51760.0,46555.0,90.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2018,H,N/A,not supported by gavi,49117.0,45595.0,93.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2019,H,N/A,not supported by gavi,50348.0,46931.0,93.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2020,H,N/A,not supported by gavi,48645.0,44879.0,92.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2021,H,N/A,not supported by gavi,49270.0,45142.0,92.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2022,H,N/A,not supported by gavi,46561.0,43147.0,93.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2023,H,N/A,not supported by gavi,N/A,N/A,93.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2024,H,N/A,not supported by gavi,42979.0,39033.0,91.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,10,Both sexes,16.8
PRT,Portugal,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,Facility-based,10,Both sexes,16.8
PRY,Paraguay,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2010,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2011,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2012,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2013,LM,N/A,not supported by gavi,117542.0,107410.0,91.0,AMR,1 dose,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2014,UM,N/A,not supported by gavi,58206.0,46632.0,80.0,AMR,1 dose,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2015,UM,N/A,not supported by gavi,58286.0,45358.0,78.0,AMR,1 dose,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2016,UM,N/A,not supported by gavi,58204.0,45935.0,79.0,AMR,1 dose,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2017,UM,N/A,not supported by gavi,58205.0,45754.0,79.0,AMR,1 dose,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2018,UM,N/A,not supported by gavi,58706.0,47053.0,80.0,AMR,1 dose,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2019,UM,N/A,not supported by gavi,59490.0,48389.0,81.0,AMR,1 dose,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2020,UM,N/A,not supported by gavi,59871.0,43335.0,72.0,AMR,1 dose,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2021,UM,N/A,not supported by gavi,60306.0,33580.0,56.0,AMR,1 dose,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2022,UM,N/A,not supported by gavi,61379.0,27596.0,45.0,AMR,1 dose,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2023,UM,N/A,not supported by gavi,62461.0,27488.0,44.0,AMR,1 dose,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2024,UM,N/A,not supported by gavi,63655.0,29919.0,47.0,AMR,1 dose,Yes,2013.0,mixed,10,Both sexes,31.0
PRY,Paraguay,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,mixed,10,Both sexes,31.0
PSE,West Bank and Gaza,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,West Bank and Gaza,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,West Bank and Gaza,2010,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,West Bank and Gaza,2011,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,West Bank and Gaza,2012,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,West Bank and Gaza,2013,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,West Bank and Gaza,2014,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,West Bank and Gaza,2015,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,West Bank and Gaza,2016,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,West Bank and Gaza,2017,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,West Bank and Gaza,2018,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,West Bank and Gaza,2019,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,West Bank and Gaza,2020,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,West Bank and Gaza,2021,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,West Bank and Gaza,2022,UM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,West Bank and Gaza,2023,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,West Bank and Gaza,2024,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PSE,Occupied Palestinian territory,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,2.2
PYF,French Polynesia,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
PYF,French Polynesia,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,10.7
QAT,Qatar,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2014,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2015,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2016,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2017,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2018,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2019,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2020,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2021,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2022,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (6 months),Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,EMR,2 doses (6 months),Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2024,H,N/A,not supported by gavi,12758.0,455.0,4.0,EMR,2 doses (6 months),Yes,2023.0,N/A,N/A,Both sexes,3.3
QAT,Qatar,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,N/A,N/A,Both sexes,3.3
ROU,Romania,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2019,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2020,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2021,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2022,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2023,H,N/A,not supported by gavi,109071.0,25333.0,23.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2024,H,N/A,not supported by gavi,107282.0,18791.0,18.0,EUR,2 doses (6 months),Yes,2023.0,Facility-based,11-14,Both sexes,34.4
ROU,Romania,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,Facility-based,11-14,Both sexes,34.4
RUS,Russian Federation,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2014,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2019,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2020,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2021,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2022,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2023,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2024,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,23.5
RUS,Russian Federation,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,23.5
RWA,Rwanda,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2010,L,Poorest,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2011,L,Low income,supported by gavi,127510.0,45381.0,36.0,AFR,1 dose,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2012,L,Low income,supported by gavi,132356.0,62207.0,47.0,AFR,1 dose,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2013,L,Low income,supported by gavi,138021.0,78672.0,57.0,AFR,1 dose,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2014,L,Low income,supported by gavi,142729.0,97056.0,68.0,AFR,1 dose,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2015,L,Initial self-financing,supported by gavi,147417.0,114433.0,78.0,AFR,1 dose,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2016,L,Initial self-financing,supported by gavi,153463.0,124820.0,81.0,AFR,1 dose,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2017,L,Initial self-financing,supported by gavi,158430.0,127868.0,81.0,AFR,1 dose,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2018,L,Initial self-financing,supported by gavi,161276.0,135652.0,84.0,AFR,1 dose,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2019,L,Initial self-financing,supported by gavi,162001.0,148675.0,92.0,AFR,1 dose,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2020,L,Initial self-financing,supported by gavi,160803.0,138930.0,86.0,AFR,1 dose,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2021,L,Initial self-financing,supported by gavi,159310.0,123138.0,77.0,AFR,1 dose,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2022,L,Initial self-financing,supported by gavi,159035.0,132884.0,84.0,AFR,1 dose,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2023,L,Initial self-financing,supported by gavi,160283.0,129083.0,81.0,AFR,1 dose,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2024,L,Initial self-financing,supported by gavi,162876.0,125325.0,77.0,AFR,1 dose,Yes,2011.0,School-based,12,Female,12.5
RWA,Rwanda,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2011.0,School-based,12,Female,12.5
SAU,Saudi Arabia,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (12 months),Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (12 months),Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (12 months),Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (12 months),Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2014,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (12 months),Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2015,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (12 months),Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2016,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (12 months),Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2017,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (12 months),Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2018,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (12 months),Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2019,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (12 months),Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2020,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (12 months),Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2021,H,N/A,not supported by gavi,N/A,N/A,0.0,EMR,2 doses (12 months),Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2022,H,N/A,not supported by gavi,257257.0,170324.0,66.0,EMR,2 doses (12 months),Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,EMR,2 doses (12 months),Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2024,H,N/A,not supported by gavi,267428.0,133083.0,50.0,EMR,2 doses (12 months),Yes,2022.0,School-based,N/A,Female,2.2
SAU,Saudi Arabia,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,School-based,N/A,Female,2.2
SDN,Sudan,2008,LM,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2009,LM,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2010,LM,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2011,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2012,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2013,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2014,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2017,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2018,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2019,L,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2020,L,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2021,L,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2022,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2023,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2024,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SDN,Sudan,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,5.4
SEN,Senegal,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2009,LM,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2010,LM,Poorest,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2011,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2012,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2013,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2014,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2015,L,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2016,L,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2017,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2018,LM,Initial self-financing,supported by gavi,N/A,N/A,N/A,AFR,2 doses (6 months),Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2019,LM,Initial self-financing,supported by gavi,211448.0,191148.0,90.0,AFR,2 doses (6 months),Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2020,LM,Preparatory transition phase,supported by gavi,215262.0,103143.0,48.0,AFR,2 doses (6 months),Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2021,LM,Preparatory transition phase,supported by gavi,217548.0,146051.0,67.0,AFR,2 doses (6 months),Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2022,LM,Preparatory transition phase,supported by gavi,217872.0,109310.0,50.0,AFR,2 doses (6 months),Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2023,LM,Preparatory transition phase,supported by gavi,217733.0,126285.0,58.0,AFR,2 doses (6 months),Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2024,LM,Preparatory transition phase,supported by gavi,218296.0,145157.0,66.0,AFR,2 doses (6 months),Yes,2018.0,Facility-based,9,Female,22.9
SEN,Senegal,2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,Facility-based,9,Female,22.9
SGP,Singapore,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,WPR,2 doses (6 months),Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2012,H,N/A,not supported by gavi,24974.0,262.0,1.0,WPR,2 doses (6 months),Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2013,H,N/A,not supported by gavi,25136.0,296.0,1.0,WPR,2 doses (6 months),Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2014,H,N/A,not supported by gavi,25091.0,426.0,2.0,WPR,2 doses (6 months),Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2015,H,N/A,not supported by gavi,24113.0,281.0,1.0,WPR,2 doses (6 months),Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2016,H,N/A,not supported by gavi,N/A,N/A,0.0,WPR,2 doses (6 months),Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2017,H,N/A,not supported by gavi,22845.0,393.0,2.0,WPR,2 doses (6 months),Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2018,H,N/A,not supported by gavi,N/A,N/A,39.0,WPR,2 doses (6 months),Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2019,H,N/A,not supported by gavi,N/A,N/A,75.0,WPR,2 doses (6 months),Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2020,H,N/A,not supported by gavi,N/A,N/A,89.0,WPR,2 doses (6 months),Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2021,H,N/A,not supported by gavi,N/A,N/A,89.0,WPR,2 doses (6 months),Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2022,H,N/A,not supported by gavi,22834.0,16817.0,74.0,WPR,2 doses (6 months),Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2023,H,N/A,not supported by gavi,22101.0,15939.0,72.0,WPR,2 doses (6 months),Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2024,H,N/A,not supported by gavi,21210.0,16512.0,78.0,WPR,2 doses (6 months),Yes,2010.0,School-based,9-26,Female,12.5
SGP,Singapore,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,9-26,Female,12.5
SLB,Solomon Islands,2008,LM,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2010,LM,Poorest,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2011,LM,Low income,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2012,LM,Low income,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2013,LM,Intermediate,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2014,LM,Intermediate,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2017,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2018,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2019,LM,Accelerated transition phase,supported by gavi,48911.0,25743.0,53.0,WPR,1 dose,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2020,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,WPR,1 dose,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2021,LM,Accelerated transition phase,supported by gavi,51747.0,3152.0,6.0,WPR,1 dose,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2022,LM,Accelerated transition phase,supported by gavi,9556.0,3413.0,36.0,WPR,1 dose,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2023,LM,Accelerated transition phase,supported by gavi,9712.0,6278.0,65.0,WPR,1 dose,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2024,LM,Accelerated transition phase,supported by gavi,9820.0,7638.0,78.0,WPR,1 dose,Yes,2019.0,mixed,9,Female,20.3
SLB,Solomon Islands,2025,N/A,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,mixed,9,Female,20.3
SLE,Sierra Leone,2008,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2009,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2010,L,Fragile,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2011,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2012,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2013,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2014,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2015,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2016,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2017,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2018,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2019,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2020,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2021,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2022,L,Initial self-financing,supported by gavi,205754.0,152258.0,74.0,AFR,1 dose,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2023,L,Initial self-financing,supported by gavi,104305.0,25033.0,24.0,AFR,1 dose,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2024,L,Initial self-financing,supported by gavi,208562.0,127223.0,61.0,AFR,1 dose,Yes,2022.0,N/A,10,Female,11.7
SLE,Sierra Leone,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,10,Female,11.7
SLV,El Salvador,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2010,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2011,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2012,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2013,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2014,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2015,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2016,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2017,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2018,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2019,LM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2020,LM,N/A,not supported by gavi,54453.0,15286.0,28.0,AMR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2021,LM,N/A,not supported by gavi,93514.0,41152.0,44.0,AMR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2022,UM,mic_never_gavi,supported by gavi,74002.0,47189.0,64.0,AMR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2023,UM,mic_never_gavi,supported by gavi,72719.0,54996.0,76.0,AMR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2024,UM,mic_never_gavi,supported by gavi,71093.0,60894.0,86.0,AMR,1 dose,Yes,2020.0,School-based,9,Both sexes,18.0
SLV,El Salvador,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2020.0,School-based,9,Both sexes,18.0
SMR,San Marino,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2012,H,N/A,not supported by gavi,170.0,32.0,19.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2013,H,N/A,not supported by gavi,164.0,26.0,16.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2014,H,N/A,not supported by gavi,152.0,29.0,19.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2015,H,N/A,not supported by gavi,162.0,17.0,10.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2016,H,N/A,not supported by gavi,146.0,29.0,20.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2017,H,N/A,not supported by gavi,163.0,60.0,37.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2018,H,N/A,not supported by gavi,147.0,88.0,60.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2019,H,N/A,not supported by gavi,N/A,N/A,65.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2020,H,N/A,not supported by gavi,N/A,N/A,67.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2021,H,N/A,not supported by gavi,N/A,N/A,39.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2022,H,N/A,not supported by gavi,N/A,N/A,52.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2023,H,N/A,not supported by gavi,N/A,N/A,58.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2024,H,N/A,not supported by gavi,N/A,N/A,62.0,EUR,2 doses (6 months),Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SMR,San Marino,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2008.0,Facility-based,11-14,Both sexes,N/A
SOM,"Somalia, Fed. Rep.",2008,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,"Somalia, Fed. Rep.",2009,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,"Somalia, Fed. Rep.",2010,L,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,"Somalia, Fed. Rep.",2011,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,"Somalia, Fed. Rep.",2012,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,"Somalia, Fed. Rep.",2013,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,"Somalia, Fed. Rep.",2014,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,"Somalia, Fed. Rep.",2015,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,"Somalia, Fed. Rep.",2016,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,"Somalia, Fed. Rep.",2017,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,"Somalia, Fed. Rep.",2018,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,"Somalia, Fed. Rep.",2019,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,"Somalia, Fed. Rep.",2020,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,"Somalia, Fed. Rep.",2021,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,"Somalia, Fed. Rep.",2022,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,"Somalia, Fed. Rep.",2023,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,"Somalia, Fed. Rep.",2024,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SOM,Somalia,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,13.8
SRB,Serbia,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2019,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2020,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2021,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2022,UM,N/A,not supported by gavi,196376.0,3800.0,2.0,EUR,2 doses (6 months),Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2023,UM,N/A,not supported by gavi,192003.0,4582.0,2.0,EUR,2 doses (6 months),Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2024,UM,N/A,not supported by gavi,189448.0,6821.0,4.0,EUR,2 doses (6 months),Yes,2022.0,N/A,N/A,Both sexes,20.5
SRB,Serbia,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,N/A,Both sexes,20.5
SSD,South Sudan,2008,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2009,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2010,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2011,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2012,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2013,LM,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2014,L,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2015,L,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2016,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2017,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2018,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2019,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2020,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2021,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2022,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2023,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2024,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
SSD,South Sudan,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.9
STP,So Tom and Prncipe,2008,LM,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,N/A,N/A,Female,12.3
STP,So Tom and Prncipe,2009,LM,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,N/A,N/A,Female,12.3
STP,So Tom and Prncipe,2010,LM,Poorest,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Female,12.3
STP,So Tom and Prncipe,2011,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Female,12.3
STP,So Tom and Prncipe,2012,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Female,12.3
STP,So Tom and Prncipe,2013,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Female,12.3
STP,So Tom and Prncipe,2014,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Female,12.3
STP,So Tom and Prncipe,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Female,12.3
STP,So Tom and Prncipe,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Female,12.3
STP,So Tom and Prncipe,2017,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Female,12.3
STP,So Tom and Prncipe,2018,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Female,12.3
STP,So Tom and Prncipe,2019,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Female,12.3
STP,So Tom and Prncipe,2020,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Female,12.3
STP,So Tom and Prncipe,2021,LM,Accelerated transition phase,supported by gavi,2710.0,2005.0,74.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Female,12.3
STP,So Tom and Prncipe,2022,LM,Accelerated transition phase,supported by gavi,2853.0,2197.0,77.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Female,12.3
STP,So Tom and Prncipe,2023,LM,Accelerated transition phase,supported by gavi,3017.0,2289.0,76.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Female,12.3
STP,So Tom and Prncipe,2024,LM,Accelerated transition phase,supported by gavi,2995.0,2248.0,75.0,AFR,1 dose,Yes,2021.0,N/A,N/A,Female,12.3
STP,Sao Tome and Principe,2025,N/A,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,N/A,N/A,Female,12.3
SUR,Suriname,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2013,UM,N/A,not supported by gavi,N/A,N/A,N/A,AMR,1 dose,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2014,UM,N/A,not supported by gavi,27580.0,15593.0,57.0,AMR,1 dose,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2015,UM,N/A,not supported by gavi,5373.0,3360.0,63.0,AMR,1 dose,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2016,UM,N/A,not supported by gavi,5424.0,1836.0,34.0,AMR,1 dose,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2017,UM,N/A,not supported by gavi,N/A,N/A,68.0,AMR,1 dose,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2018,UM,N/A,not supported by gavi,N/A,N/A,68.0,AMR,1 dose,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2019,UM,N/A,not supported by gavi,5436.0,2580.0,47.0,AMR,1 dose,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2020,UM,N/A,not supported by gavi,5420.0,861.0,16.0,AMR,1 dose,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2021,UM,N/A,not supported by gavi,5437.0,175.0,3.0,AMR,1 dose,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2022,UM,mic_never_gavi,supported by gavi,5465.0,418.0,8.0,AMR,1 dose,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2023,UM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,AMR,1 dose,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2024,UM,mic_never_gavi,supported by gavi,5443.0,713.0,13.0,AMR,1 dose,Yes,2013.0,School-based,9-13,Both sexes,27.3
SUR,Suriname,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,School-based,9-13,Both sexes,27.3
SVK,Slovak Republic,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2013,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2014,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2015,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2016,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2017,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2018,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2019,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2020,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2021,H,N/A,not supported by gavi,N/A,N/A,0.0,EUR,2 doses (6 months),Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2022,H,N/A,not supported by gavi,N/A,N/A,33.0,EUR,2 doses (6 months),Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2023,H,N/A,not supported by gavi,N/A,N/A,44.0,EUR,2 doses (6 months),Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2024,H,N/A,not supported by gavi,29859.0,10890.0,36.0,EUR,2 doses (6 months),Yes,2022.0,N/A,12,Both sexes,19.9
SVK,Slovak Republic,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,12,Both sexes,19.9
SVN,Slovenia,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2010,H,N/A,not supported by gavi,N/A,N/A,44.0,EUR,2 doses (6 months),Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2011,H,N/A,not supported by gavi,N/A,N/A,47.0,EUR,2 doses (6 months),Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2012,H,N/A,not supported by gavi,N/A,N/A,50.0,EUR,2 doses (6 months),Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2013,H,N/A,not supported by gavi,N/A,N/A,38.0,EUR,2 doses (6 months),Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2014,H,N/A,not supported by gavi,N/A,N/A,44.0,EUR,2 doses (6 months),Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2015,H,N/A,not supported by gavi,N/A,N/A,42.0,EUR,2 doses (6 months),Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2016,H,N/A,not supported by gavi,N/A,N/A,42.0,EUR,2 doses (6 months),Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2017,H,N/A,not supported by gavi,N/A,N/A,44.0,EUR,2 doses (6 months),Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2018,H,N/A,not supported by gavi,N/A,N/A,48.0,EUR,2 doses (6 months),Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2019,H,N/A,not supported by gavi,N/A,N/A,57.0,EUR,2 doses (6 months),Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2020,H,N/A,not supported by gavi,N/A,N/A,56.0,EUR,2 doses (6 months),Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2021,H,N/A,not supported by gavi,N/A,N/A,38.0,EUR,2 doses (6 months),Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2022,H,N/A,not supported by gavi,N/A,N/A,45.0,EUR,2 doses (6 months),Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2023,H,N/A,not supported by gavi,N/A,N/A,45.0,EUR,2 doses (6 months),Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2024,H,N/A,not supported by gavi,N/A,N/A,43.0,EUR,2 doses (6 months),Yes,2009.0,School-based,11,Both sexes,11.4
SVN,Slovenia,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2009.0,School-based,11,Both sexes,11.4
SWE,Sweden,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,EUR,2 doses (6 months),Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2015,H,N/A,not supported by gavi,N/A,N/A,81.0,EUR,2 doses (6 months),Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2016,H,N/A,not supported by gavi,N/A,N/A,80.0,EUR,2 doses (6 months),Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2017,H,N/A,not supported by gavi,N/A,N/A,78.0,EUR,2 doses (6 months),Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2018,H,N/A,not supported by gavi,N/A,N/A,82.0,EUR,2 doses (6 months),Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2019,H,N/A,not supported by gavi,N/A,N/A,86.0,EUR,2 doses (6 months),Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2020,H,N/A,not supported by gavi,N/A,N/A,89.0,EUR,2 doses (6 months),Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2021,H,N/A,not supported by gavi,N/A,N/A,87.0,EUR,2 doses (6 months),Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2022,H,N/A,not supported by gavi,N/A,N/A,92.0,EUR,2 doses (6 months),Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2023,H,N/A,not supported by gavi,N/A,N/A,92.0,EUR,2 doses (6 months),Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2024,H,N/A,not supported by gavi,N/A,N/A,91.0,EUR,2 doses (6 months),Yes,2010.0,School-based,10-11,Both sexes,11.0
SWE,Sweden,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2010.0,School-based,10-11,Both sexes,11.0
SWZ,Eswatini,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2010,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2011,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2012,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2013,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2014,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2015,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2016,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2017,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2018,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2019,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2020,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2021,LM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2022,LM,mic_never_gavi,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2023,LM,mic_never_gavi,supported by gavi,80742.0,49448.0,61.0,AFR,1 dose,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2024,LM,mic_never_gavi,supported by gavi,37104.0,11233.0,30.0,AFR,1 dose,Yes,2023.0,School-based,9,Female,69.4
SWZ,Eswatini,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,9,Female,69.4
SXM,Sint Maarten (Dutch part),2008,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2009,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SXM,Sint Maarten (Dutch part),2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
SYC,Seychelles,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,2 doses (6 months),Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2014,H,N/A,not supported by gavi,688.0,534.0,78.0,AFR,2 doses (6 months),Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2015,H,N/A,not supported by gavi,698.0,618.0,89.0,AFR,2 doses (6 months),Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2016,H,N/A,not supported by gavi,707.0,668.0,94.0,AFR,2 doses (6 months),Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2017,H,N/A,not supported by gavi,719.0,616.0,86.0,AFR,2 doses (6 months),Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2018,H,N/A,not supported by gavi,745.0,680.0,91.0,AFR,2 doses (6 months),Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2019,H,N/A,not supported by gavi,769.0,705.0,92.0,AFR,2 doses (6 months),Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2020,H,N/A,not supported by gavi,806.0,780.0,97.0,AFR,2 doses (6 months),Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2021,H,N/A,not supported by gavi,816.0,628.0,77.0,AFR,2 doses (6 months),Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2022,H,N/A,not supported by gavi,828.0,755.0,91.0,AFR,2 doses (6 months),Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2023,H,N/A,not supported by gavi,830.0,670.0,81.0,AFR,2 doses (6 months),Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2024,H,N/A,not supported by gavi,829.0,588.0,71.0,AFR,2 doses (6 months),Yes,2014.0,School-based,10,Both sexes,N/A
SYC,Seychelles,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,10,Both sexes,N/A
SYR,Syrian Arab Republic,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2010,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2011,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2012,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2013,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2014,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2015,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2016,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2017,L,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2018,L,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2019,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2020,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2021,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2022,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2023,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2024,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
SYR,Syrian Arab Republic,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,2.1
TCA,Turks and Caicos Islands,2008,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCA,Turks and Caicos Islands,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TCD,Chad,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2010,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2011,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2012,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2013,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2014,L,Low income,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2015,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2016,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2017,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2018,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2019,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2020,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2021,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2022,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2023,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2024,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TCD,Chad,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,12.7
TGO,Togo,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2010,L,Poorest,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2011,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2012,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2013,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2014,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2015,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2016,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2017,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2018,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2019,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2020,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2021,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2022,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2023,L,Initial self-financing,supported by gavi,679292.0,304457.0,45.0,AFR,1 dose,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2024,L,Initial self-financing,supported by gavi,119083.0,42724.0,36.0,AFR,1 dose,Yes,2023.0,School-based,9-14,Female,11.7
TGO,Togo,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,9-14,Female,11.7
THA,Thailand,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2017,UM,N/A,not supported by gavi,423694.0,290962.0,69.0,SEAR,1 dose,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2018,UM,N/A,not supported by gavi,415839.0,308576.0,74.0,SEAR,1 dose,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2019,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2020,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2021,UM,N/A,not supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2022,UM,N/A,not supported by gavi,N/A,N/A,N/A,SEAR,1 dose,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2023,UM,N/A,not supported by gavi,791856.0,371319.0,47.0,SEAR,1 dose,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2024,UM,N/A,not supported by gavi,510074.0,289727.0,57.0,SEAR,1 dose,Yes,2017.0,School-based,11,Female,24.1
THA,Thailand,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,School-based,11,Female,24.1
TJK,Tajikistan,2008,L,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2009,L,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2010,L,Intermediate,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2011,L,Low income,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2012,L,Low income,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2013,L,Low income,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2014,LM,Low income,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2015,LM,Initial self-financing,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2017,L,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2018,L,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2019,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2020,LM,Initial self-financing,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2021,LM,Initial self-financing,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2022,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2023,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2024,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2025.0,School-based,10-14,Female,5.6
TJK,Tajikistan,2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,10-14,Female,5.6
TKM,Turkmenistan,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2010,LM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2016,UM,N/A,not supported by gavi,52566.0,47242.0,90.0,EUR,1 dose,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2017,UM,N/A,not supported by gavi,56428.0,54349.0,96.0,EUR,1 dose,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2018,UM,N/A,not supported by gavi,61038.0,59900.0,98.0,EUR,1 dose,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2019,UM,N/A,not supported by gavi,65516.0,67921.0,99.0,EUR,1 dose,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2020,UM,N/A,not supported by gavi,69668.0,72044.0,99.0,EUR,1 dose,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2021,UM,N/A,not supported by gavi,73403.0,72608.0,99.0,EUR,1 dose,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2022,UM,N/A,not supported by gavi,76370.0,75360.0,99.0,EUR,1 dose,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2023,UM,N/A,not supported by gavi,78505.0,77526.0,99.0,EUR,1 dose,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2024,UM,N/A,not supported by gavi,80088.0,77913.0,97.0,EUR,1 dose,Yes,2016.0,mixed,9,Both sexes,14.3
TKM,Turkmenistan,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2016.0,mixed,9,Both sexes,14.3
TLS,Timor-Leste,2008,LM,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2009,LM,Fragile,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2010,LM,Fragile,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2011,LM,Graduating,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2012,LM,Intermediate,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2013,LM,Intermediate,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2014,LM,Graduating,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2015,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2016,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2017,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2018,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2019,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2020,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2021,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2022,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2023,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,SEAR,1 dose,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2024,LM,Fully self-financing,supported by gavi,61374.0,61820.0,99.0,SEAR,1 dose,Yes,2024.0,School-based,11-14,Female,11.4
TLS,Timor-Leste,2025,N/A,Fully self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2024.0,School-based,11-14,Female,11.4
TON,Tonga,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2010,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2011,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2015,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2019,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2020,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2021,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2022,UM,mic_never_gavi,supported by gavi,9217.0,1112.0,12.0,WPR,1 dose,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2023,UM,mic_never_gavi,supported by gavi,6196.0,1529.0,25.0,WPR,1 dose,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2024,UM,mic_never_gavi,supported by gavi,4306.0,2889.0,67.0,WPR,1 dose,Yes,2022.0,N/A,N/A,Female,N/A
TON,Tonga,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,N/A,N/A,Female,N/A
TTO,Trinidad and Tobago,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2010,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2011,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2013,H,N/A,not supported by gavi,9040.0,1699.0,19.0,AMR,2 doses (6 months),Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,AMR,2 doses (6 months),Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2015,H,N/A,not supported by gavi,19336.0,2508.0,13.0,AMR,2 doses (6 months),Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2016,H,N/A,not supported by gavi,19449.0,9841.0,51.0,AMR,2 doses (6 months),Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2017,H,N/A,not supported by gavi,19762.0,3991.0,20.0,AMR,2 doses (6 months),Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2018,H,N/A,not supported by gavi,20206.0,5999.0,30.0,AMR,2 doses (6 months),Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2019,H,N/A,not supported by gavi,20474.0,3469.0,17.0,AMR,2 doses (6 months),Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,AMR,2 doses (6 months),Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2021,H,N/A,not supported by gavi,20364.0,3761.0,18.0,AMR,2 doses (6 months),Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2022,H,N/A,not supported by gavi,20492.0,4609.0,22.0,AMR,2 doses (6 months),Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2023,H,N/A,not supported by gavi,9329.0,3168.0,34.0,AMR,2 doses (6 months),Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2024,H,N/A,not supported by gavi,9272.0,3535.0,38.0,AMR,2 doses (6 months),Yes,2013.0,mixed,11-15,Both sexes,26.9
TTO,Trinidad and Tobago,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,mixed,11-15,Both sexes,26.9
TUN,Tunisia,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2010,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2011,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2012,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2013,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2014,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2015,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2016,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2017,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2018,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2019,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2020,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2021,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2022,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2023,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2024,LM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUN,Tunisia,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2025.0,School-based,12,Female,6.8
TUR,Trkiye,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2019,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2020,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2021,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2022,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2023,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2024,UM,N/A,not supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,13,Both sexes,6.0
TUR,Trkiye,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,13,Both sexes,6.0
TUV,Tuvalu,2008,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2010,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2019,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2020,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2021,UM,N/A,not supported by gavi,111.0,88.0,79.0,WPR,1 dose,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2022,UM,mic_never_gavi,supported by gavi,99.0,79.0,80.0,WPR,1 dose,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2023,UM,mic_never_gavi,supported by gavi,108.0,91.0,84.0,WPR,1 dose,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2024,UM,mic_never_gavi,supported by gavi,105.0,74.0,70.0,WPR,1 dose,Yes,2021.0,N/A,N/A,Female,N/A
TUV,Tuvalu,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2021.0,N/A,N/A,Female,N/A
TWN,"Taiwan, China",2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TWN,"Taiwan, China",2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
TZA,Tanzania,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,mixed,9,Female,34.3
TZA,Tanzania,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,mixed,9,Female,34.3
TZA,Tanzania,2010,L,Poorest,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,mixed,9,Female,34.3
TZA,Tanzania,2011,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,mixed,9,Female,34.3
TZA,Tanzania,2012,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,mixed,9,Female,34.3
TZA,Tanzania,2013,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,mixed,9,Female,34.3
TZA,Tanzania,2014,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,mixed,9,Female,34.3
TZA,Tanzania,2015,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,mixed,9,Female,34.3
TZA,Tanzania,2016,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,mixed,9,Female,34.3
TZA,Tanzania,2017,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,mixed,9,Female,34.3
TZA,Tanzania,2018,L,Initial self-financing,supported by gavi,691442.0,339643.0,49.0,AFR,1 dose,Yes,2018.0,mixed,9,Female,34.3
TZA,Tanzania,2019,LM,Initial self-financing,supported by gavi,716346.0,534231.0,75.0,AFR,1 dose,Yes,2018.0,mixed,9,Female,34.3
TZA,Tanzania,2020,LM,Initial self-financing,supported by gavi,735942.0,585292.0,80.0,AFR,1 dose,Yes,2018.0,mixed,9,Female,34.3
TZA,Tanzania,2021,LM,Initial self-financing,supported by gavi,748845.0,535298.0,71.0,AFR,1 dose,Yes,2018.0,mixed,9,Female,34.3
TZA,Tanzania,2022,LM,Preparatory transition phase,supported by gavi,760235.0,617980.0,81.0,AFR,1 dose,Yes,2018.0,mixed,9,Female,34.3
TZA,Tanzania,2023,LM,Preparatory transition phase,supported by gavi,854187.0,966841.0,99.0,AFR,1 dose,Yes,2018.0,mixed,9,Female,34.3
TZA,Tanzania,2024,LM,Preparatory transition phase,supported by gavi,5845290.0,5478116.0,94.0,AFR,1 dose,Yes,2018.0,mixed,9,Female,34.3
TZA,"Tanzania, United Republic of",2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,mixed,9,Female,34.3
UGA,Uganda,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2010,L,Poorest,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2011,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2012,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2013,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2014,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2015,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,AFR,1 dose,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2016,L,Initial self-financing,supported by gavi,574275.0,709558.0,99.0,AFR,1 dose,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2017,L,Initial self-financing,supported by gavi,587107.0,725350.0,99.0,AFR,1 dose,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2018,L,Initial self-financing,supported by gavi,599082.0,755428.0,99.0,AFR,1 dose,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2019,L,Initial self-financing,supported by gavi,612794.0,693789.0,99.0,AFR,1 dose,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2020,L,Initial self-financing,supported by gavi,628357.0,483067.0,77.0,AFR,1 dose,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2021,L,Initial self-financing,supported by gavi,642034.0,499667.0,78.0,AFR,1 dose,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2022,L,Initial self-financing,supported by gavi,1294726.0,1134906.0,88.0,AFR,1 dose,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2023,L,Initial self-financing,supported by gavi,700823.0,693815.0,99.0,AFR,1 dose,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2024,L,Initial self-financing,supported by gavi,1331840.0,1266393.0,95.0,AFR,1 dose,Yes,2015.0,School-based,10,Female,28.3
UGA,Uganda,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2015.0,School-based,10,Female,28.3
UKR,Ukraine,2008,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2009,LM,Least Poor,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2010,LM,Least Poor,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2011,LM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2012,LM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2013,LM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2014,LM,Graduating,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2015,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2016,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2017,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2018,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2019,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2020,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2021,LM,Fully self-financing,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2022,LM,mic_former_gavi,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2023,UM,mic_former_gavi,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2024,UM,mic_former_gavi,supported by gavi,N/A,N/A,0.0,EUR,Not yet introduced,No,N/A,N/A,N/A,N/A,22.3
UKR,Ukraine,2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,22.3
URY,Uruguay,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2012,H,N/A,not supported by gavi,N/A,N/A,0.0,AMR,2 doses (6 months),Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2013,H,N/A,not supported by gavi,N/A,N/A,N/A,AMR,2 doses (6 months),Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2014,H,N/A,not supported by gavi,N/A,N/A,N/A,AMR,2 doses (6 months),Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2015,H,N/A,not supported by gavi,23808.0,8348.0,35.0,AMR,2 doses (6 months),Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2016,H,N/A,not supported by gavi,23422.0,14446.0,62.0,AMR,2 doses (6 months),Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2017,H,N/A,not supported by gavi,N/A,N/A,68.0,AMR,2 doses (6 months),Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2018,H,N/A,not supported by gavi,23247.0,17512.0,75.0,AMR,2 doses (6 months),Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2019,H,N/A,not supported by gavi,22975.0,15719.0,68.0,AMR,2 doses (6 months),Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2020,H,N/A,not supported by gavi,22773.0,13117.0,58.0,AMR,2 doses (6 months),Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2021,H,N/A,not supported by gavi,22663.0,12351.0,54.0,AMR,2 doses (6 months),Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2022,H,N/A,not supported by gavi,22631.0,12727.0,56.0,AMR,2 doses (6 months),Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2023,H,N/A,not supported by gavi,N/A,N/A,67.0,AMR,2 doses (6 months),Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2024,H,N/A,not supported by gavi,22538.0,17261.0,77.0,AMR,2 doses (6 months),Yes,2013.0,Facility-based,11,Both sexes,20.9
URY,Uruguay,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2013.0,Facility-based,11,Both sexes,20.9
USA,United States,2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2010,H,N/A,not supported by gavi,N/A,N/A,39.0,AMR,1 dose,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2011,H,N/A,not supported by gavi,N/A,N/A,42.0,AMR,1 dose,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2012,H,N/A,not supported by gavi,N/A,N/A,47.0,AMR,1 dose,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2013,H,N/A,not supported by gavi,N/A,N/A,51.0,AMR,1 dose,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2014,H,N/A,not supported by gavi,N/A,N/A,51.0,AMR,1 dose,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2015,H,N/A,not supported by gavi,N/A,N/A,56.0,AMR,1 dose,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2016,H,N/A,not supported by gavi,N/A,N/A,55.0,AMR,1 dose,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2017,H,N/A,not supported by gavi,N/A,N/A,65.0,AMR,1 dose,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2018,H,N/A,not supported by gavi,N/A,N/A,61.0,AMR,1 dose,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2019,H,N/A,not supported by gavi,N/A,N/A,68.0,AMR,1 dose,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2020,H,N/A,not supported by gavi,N/A,N/A,71.0,AMR,1 dose,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2021,H,N/A,not supported by gavi,N/A,N/A,73.0,AMR,1 dose,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2022,H,N/A,not supported by gavi,N/A,N/A,73.0,AMR,1 dose,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2023,H,N/A,not supported by gavi,N/A,N/A,74.0,AMR,1 dose,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2024,H,N/A,not supported by gavi,N/A,N/A,74.0,AMR,1 dose,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
USA,United States,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2006.0,Facility-based,11-12,Both sexes,8.2
UZB,Uzbekistan,2008,L,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2009,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2010,LM,Intermediate,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2011,LM,Intermediate,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2012,LM,Intermediate,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2013,LM,Intermediate,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2014,LM,Intermediate,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2015,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2016,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2017,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2018,LM,Accelerated transition phase,supported by gavi,N/A,N/A,0.0,EUR,1 dose,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2019,LM,Accelerated transition phase,supported by gavi,300322.0,291766.0,97.0,EUR,1 dose,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2020,LM,Accelerated transition phase,supported by gavi,297257.0,270266.0,91.0,EUR,1 dose,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2021,LM,Accelerated transition phase,supported by gavi,1155811.0,1157868.0,99.0,EUR,1 dose,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2022,LM,mic_former_gavi,supported by gavi,373945.0,373000.0,99.0,EUR,1 dose,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2023,LM,mic_former_gavi,supported by gavi,329873.0,305143.0,93.0,EUR,1 dose,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2024,LM,mic_former_gavi,supported by gavi,370761.0,339114.0,91.0,EUR,1 dose,Yes,2019.0,School-based,9,Both sexes,15.4
UZB,Uzbekistan,2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9,Both sexes,15.4
VCT,St. Vincent and the Grenadines,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,School-based,11-12,Female,N/A
VCT,St. Vincent and the Grenadines,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,School-based,11-12,Female,N/A
VCT,St. Vincent and the Grenadines,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Female,N/A
VCT,St. Vincent and the Grenadines,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Female,N/A
VCT,St. Vincent and the Grenadines,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Female,N/A
VCT,St. Vincent and the Grenadines,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Female,N/A
VCT,St. Vincent and the Grenadines,2014,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Female,N/A
VCT,St. Vincent and the Grenadines,2015,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Female,N/A
VCT,St. Vincent and the Grenadines,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Female,N/A
VCT,St. Vincent and the Grenadines,2017,UM,N/A,not supported by gavi,785.0,123.0,16.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Female,N/A
VCT,St. Vincent and the Grenadines,2018,UM,N/A,not supported by gavi,795.0,32.0,4.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Female,N/A
VCT,St. Vincent and the Grenadines,2019,UM,N/A,not supported by gavi,796.0,86.0,11.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Female,N/A
VCT,St. Vincent and the Grenadines,2020,UM,N/A,not supported by gavi,786.0,26.0,3.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Female,N/A
VCT,St. Vincent and the Grenadines,2021,UM,N/A,not supported by gavi,N/A,N/A,N/A,AMR,1 dose,Yes,2017.0,School-based,11-12,Female,N/A
VCT,St. Vincent and the Grenadines,2022,UM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,AMR,1 dose,Yes,2017.0,School-based,11-12,Female,N/A
VCT,St. Vincent and the Grenadines,2023,UM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,AMR,1 dose,Yes,2017.0,School-based,11-12,Female,N/A
VCT,St. Vincent and the Grenadines,2024,UM,mic_never_gavi,supported by gavi,792.0,66.0,8.0,AMR,1 dose,Yes,2017.0,School-based,11-12,Female,N/A
VCT,Saint Vincent and the Grenadines,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2017.0,School-based,11-12,Female,N/A
VEN,"Venezuela, RB",2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,"Venezuela, RB",2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,"Venezuela, RB",2010,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,"Venezuela, RB",2011,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,"Venezuela, RB",2012,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,"Venezuela, RB",2013,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,"Venezuela, RB",2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,"Venezuela, RB",2015,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,"Venezuela, RB",2016,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,"Venezuela, RB",2017,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,"Venezuela, RB",2018,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,"Venezuela, RB",2019,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,"Venezuela, RB",2020,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,"Venezuela, RB",2021,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,"Venezuela, RB",2022,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,"Venezuela, RB",2023,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,"Venezuela, RB",2024,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VEN,Venezuela,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,26.7
VGB,British Virgin Islands,2008,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2009,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2010,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2011,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2012,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2013,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2014,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VGB,British Virgin Islands,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2008,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2009,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2010,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2011,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2012,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2013,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2014,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2015,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2016,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2017,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2018,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2019,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2020,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2021,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2022,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2023,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2024,H,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VIR,Virgin Islands (U.S.),2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
VNM,Viet Nam,2008,L,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2009,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2010,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2011,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2012,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2013,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2014,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2015,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2016,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2017,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2018,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2019,LM,Accelerated transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2020,LM,Fully self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2021,LM,Fully self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2022,LM,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2023,LM,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2024,LM,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VNM,Viet Nam,2025,N/A,mic_former_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,9.3
VUT,Vanuatu,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2010,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2011,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2012,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2013,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2014,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2015,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2016,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2017,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2018,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2019,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2020,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2021,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2022,LM,mic_never_gavi,supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2023,LM,mic_never_gavi,supported by gavi,3971.0,1801.0,45.0,WPR,1 dose,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2024,LM,mic_never_gavi,supported by gavi,19076.0,8198.0,43.0,WPR,1 dose,Yes,2023.0,School-based,9,Female,14.5
VUT,Vanuatu,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2023.0,School-based,9,Female,14.5
WSM,Samoa,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2010,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2011,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2012,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2013,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2014,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2015,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2016,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2017,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2018,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2019,UM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2020,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2021,LM,N/A,not supported by gavi,N/A,N/A,0.0,WPR,1 dose,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2022,LM,mic_never_gavi,supported by gavi,9862.0,8611.0,87.0,WPR,1 dose,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2023,LM,mic_never_gavi,supported by gavi,2412.0,2101.0,87.0,WPR,1 dose,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2024,UM,mic_never_gavi,supported by gavi,10824.0,6875.0,64.0,WPR,1 dose,Yes,2022.0,School-based,10-13,Female,11.3
WSM,Samoa,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2022.0,School-based,10-13,Female,11.3
XKX,Kosovo,2008,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2009,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2010,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2011,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2012,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2013,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2014,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2015,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2016,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2017,LM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2018,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2019,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2020,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2021,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2022,UM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2023,UM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2024,UM,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
XKX,Kosovo,2025,N/A,mic_never_gavi,supported by gavi,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
YEM,"Yemen, Rep.",2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,"Yemen, Rep.",2009,LM,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,"Yemen, Rep.",2010,LM,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,"Yemen, Rep.",2011,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,"Yemen, Rep.",2012,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,"Yemen, Rep.",2013,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,"Yemen, Rep.",2014,LM,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,"Yemen, Rep.",2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,"Yemen, Rep.",2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,"Yemen, Rep.",2017,L,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,"Yemen, Rep.",2018,L,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,"Yemen, Rep.",2019,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,"Yemen, Rep.",2020,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,"Yemen, Rep.",2021,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,"Yemen, Rep.",2022,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,"Yemen, Rep.",2023,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,"Yemen, Rep.",2024,L,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
YEM,Yemen,2025,N/A,Initial self-financing,supported by gavi,N/A,N/A,N/A,N/A,N/A,No,N/A,N/A,N/A,N/A,1.4
ZAF,South Africa,2008,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2009,UM,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2010,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2011,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2012,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2013,UM,N/A,not supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2014,UM,N/A,not supported by gavi,502784.0,419520.0,83.0,AFR,1 dose,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2015,UM,N/A,not supported by gavi,521779.0,427400.0,82.0,AFR,1 dose,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2016,UM,N/A,not supported by gavi,533534.0,418970.0,79.0,AFR,1 dose,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2017,UM,N/A,not supported by gavi,549306.0,378781.0,69.0,AFR,1 dose,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2018,UM,N/A,not supported by gavi,N/A,N/A,69.0,AFR,1 dose,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2019,UM,N/A,not supported by gavi,N/A,N/A,69.0,AFR,1 dose,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2020,UM,N/A,not supported by gavi,536644.0,19091.0,4.0,AFR,1 dose,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2021,UM,N/A,not supported by gavi,1065517.0,413770.0,39.0,AFR,1 dose,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2022,UM,N/A,not supported by gavi,N/A,N/A,41.0,AFR,1 dose,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2023,UM,N/A,not supported by gavi,517793.0,399020.0,77.0,AFR,1 dose,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2024,UM,N/A,not supported by gavi,512080.0,405299.0,79.0,AFR,1 dose,Yes,2014.0,School-based,9,Female,34.1
ZAF,South Africa,2025,N/A,N/A,not supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2014.0,School-based,9,Female,34.1
ZMB,Zambia,2008,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2009,L,Poorest,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2010,LM,Poorest,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2011,LM,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2012,LM,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2013,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2014,LM,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2015,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2016,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2017,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2018,LM,Preparatory transition phase,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2019,LM,Preparatory transition phase,supported by gavi,226033.0,252051.0,99.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2020,LM,Preparatory transition phase,supported by gavi,234832.0,171432.0,73.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2021,L,Preparatory transition phase,supported by gavi,242645.0,106398.0,44.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2022,LM,Preparatory transition phase,supported by gavi,249409.0,163970.0,66.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2023,LM,Initial self-financing,supported by gavi,1614488.0,911139.0,56.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2024,LM,Preparatory transition phase,supported by gavi,283312.0,170435.0,60.0,AFR,1 dose,Yes,2019.0,School-based,9,Female,37.0
ZMB,Zambia,2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2019.0,School-based,9,Female,37.0
ZWE,Zimbabwe,2008,L,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2009,L,Intermediate,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2010,L,Intermediate,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2011,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2012,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2013,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2014,L,Low income,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2015,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2016,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2017,L,Initial self-financing,supported by gavi,N/A,N/A,0.0,AFR,1 dose,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2018,LM,Initial self-financing,supported by gavi,954630.0,751367.0,79.0,AFR,1 dose,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2019,LM,Initial self-financing,supported by gavi,208014.0,180703.0,87.0,AFR,1 dose,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2020,LM,Preparatory transition phase,supported by gavi,216967.0,0.0,0.0,AFR,1 dose,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2021,LM,Preparatory transition phase,supported by gavi,440453.0,278070.0,63.0,AFR,1 dose,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2022,LM,Preparatory transition phase,supported by gavi,229257.0,13681.0,6.0,AFR,1 dose,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2023,LM,Preparatory transition phase,supported by gavi,230885.0,121765.0,53.0,AFR,1 dose,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2024,LM,Preparatory transition phase,supported by gavi,228192.0,183148.0,80.0,AFR,1 dose,Yes,2018.0,mixed,10,Female,44.0
ZWE,Zimbabwe,2025,N/A,Preparatory transition phase,supported by gavi,N/A,N/A,N/A,N/A,N/A,Yes,2018.0,mixed,10,Female,44.0
